Home
›
Videos
›
Dermbits
›
Coverage Lags Behind Innovation

#top-leaderboard-ads, .stickyads { position: static !important; }

What do you do when coverage lags behind innovation?

Featuring:

EDErik Domingues, MDFaculty

Updated:Aug 18, 2026

When does combination therapy complicate access—and how do you navigate it?

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

What have you learned from patients who have remained on tildrakizumab long term?

What have you learned from patients who have remained on tildrakizumab long term?

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

Are there patients you consider medically complex who might not fit the traditional definition?

Are there patients you consider medically complex who might not fit the traditional definition?

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

What misconceptions do patients commonly have about field therapy before they ever begin treatment?

What misconceptions do patients commonly have about field therapy before they ever begin treatment?

How do you decide when a patient should transition from lesion-directed treatment to field therapy?

How do you decide when a patient should transition from lesion-directed treatment to field therapy?

What should clinicians know about ordering tirbanibulin in the EMR to avoid confusion regarding quantity or packet selection?

What should clinicians know about ordering tirbanibulin in the EMR to avoid confusion regarding quantity or packet selection?

What misconceptions do patients sometimes have about evaluating response after tirbanibulin treatment?

What misconceptions do patients sometimes have about evaluating response after tirbanibulin treatment?

Before starting tirbanibulin, what do you tell patients about the overall treatment timeline, including when they should expect you to evaluate the results?

Before starting tirbanibulin, what do you tell patients about the overall treatment timeline, including when they should expect you to evaluate the results?

Can you describe a patient scenario in which tirbanibulin allowed you to move forward with field therapy during the summer rather than delaying treatment until a different season?

Can you describe a patient scenario in which tirbanibulin allowed you to move forward with field therapy during the summer rather than delaying treatment until a different season?

What do dermatologists sometimes overlook about apremilast when evaluating today’s treatment options?

What do dermatologists sometimes overlook about apremilast when evaluating today’s treatment options?

Which patients tend to surprise you with how well they do on apremilast?

Which patients tend to surprise you with how well they do on apremilast?

In what situations do you use apremilast alongside other psoriasis therapies?

In what situations do you use apremilast alongside other psoriasis therapies?

What has real-world experience taught us about apremilast that clinical trials alone could not?

What has real-world experience taught us about apremilast that clinical trials alone could not?

How do patient-defined treatment goals differ from clinician-defined treatment goals?

How do patient-defined treatment goals differ from clinician-defined treatment goals?

What aspects of living with psoriasis do clinicians sometimes underestimate?

What aspects of living with psoriasis do clinicians sometimes underestimate?

In an increasingly crowded psoriasis landscape, where does tildrakizumab fit for you clinically today?

In an increasingly crowded psoriasis landscape, where does tildrakizumab fit for you clinically today?

When you look at long-term data for tildrakizumab, what aspects feel most clinically meaningful in real-world practice?

When you look at long-term data for tildrakizumab, what aspects feel most clinically meaningful in real-world practice?

What types of treatment goals or patient expectations align particularly well with your experience using tildrakizumab?

What types of treatment goals or patient expectations align particularly well with your experience using tildrakizumab?

Has your experience with tildrakizumab changed the way you define treatment success in psoriasis?

Has your experience with tildrakizumab changed the way you define treatment success in psoriasis?

How has the definition of treatment success in psoriasis evolved over the last several years?

How has the definition of treatment success in psoriasis evolved over the last several years?

What aspects of psoriasis management become more challenging over the long term than they may initially appear?

What aspects of psoriasis management become more challenging over the long term than they may initially appear?

How do you decide when maintaining a patient successfully on therapy is more valuable than pursuing something newer or different?

How do you decide when maintaining a patient successfully on therapy is more valuable than pursuing something newer or different?

What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?

What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone?

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone?

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?

How do you set treatment goals with apremilast differently than you might with other systemic therapies?

How do you set treatment goals with apremilast differently than you might with other systemic therapies?

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?

What factors most strongly influence whether patients feel successful on apremilast?

What factors most strongly influence whether patients feel successful on apremilast?

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?

What do you do when coverage lags behind innovation?

What do you do when coverage lags behind innovation?

When does combination therapy complicate access—and how do you navigate it?

When does combination therapy complicate access—and how do you navigate it?

How do you manage access for patients with limited follow-up reliability?

How do you manage access for patients with limited follow-up reliability?

What documentation supports treatment escalation in stable but symptomatic disease?

What documentation supports treatment escalation in stable but symptomatic disease?

What documentation supports continued use of ruxolitinib over time?

What documentation supports continued use of ruxolitinib over time?

What clinical context supports ruxolitinib over other topical options?

What clinical context supports ruxolitinib over other topical options?

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?

What are the most common adherence challenges you see with topical treatments in vitiligo?

What are the most common adherence challenges you see with topical treatments in vitiligo?

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?

How do you balance access realities with ideal treatment plans?

How do you balance access realities with ideal treatment plans?

How do you handle denials for FDA-approved therapies?

How do you handle denials for FDA-approved therapies?

How do you handle coverage for patients switching insurance mid-treatment?

How do you handle coverage for patients switching insurance mid-treatment?

What’s your approach when payer criteria conflict with clinical guidelines?

What’s your approach when payer criteria conflict with clinical guidelines?

What helps secure approval for ruxolitinib in patients with limited BSA?

What helps secure approval for ruxolitinib in patients with limited BSA?

How do you position ruxolitinib after partial response to prior therapy?

How do you position ruxolitinib after partial response to prior therapy?

What is the mechanism of action of apremilast?

What is the mechanism of action of apremilast?

In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy?

In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy?

What do dermatologists sometimes overlook about apremilast when focusing on newer therapies?

What do dermatologists sometimes overlook about apremilast when focusing on newer therapies?

What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast?

What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast?

How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals?

How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals?

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?

What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD?

What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD?

Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience?

Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience?

Where does tapinarof fit in your current treatment approach for AD?

Where does tapinarof fit in your current treatment approach for AD?

Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful?

Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful?

Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice?

Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice?

How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies?

How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies?

When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin?

When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin?

Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids?

Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids?

Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes?

Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes?

With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches?

With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches?

In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions?

In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions?

Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked?

Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked?

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

Are there particular comorbidity profiles where apremilast feels especially appropriate?

Are there particular comorbidity profiles where apremilast feels especially appropriate?

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

What lifestyle or occupational factors make oral therapy particularly appealing?

What lifestyle or occupational factors make oral therapy particularly appealing?

How do you document quality-of-life impact in vitiligo or atopic dermatitis?

How do you document quality-of-life impact in vitiligo or atopic dermatitis?

Which clinical metrics carry the most weight with payers?

Which clinical metrics carry the most weight with payers?

How do you justify nonsteroidal therapy after steroid failure?

How do you justify nonsteroidal therapy after steroid failure?

When is a peer-to-peer review worth pursuing?

When is a peer-to-peer review worth pursuing?

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?

When is step therapy inappropriate before ruxolitinib cream?

When is step therapy inappropriate before ruxolitinib cream?

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

When apremilast first launched, how was it positioned, and what do we understand differently now?

When apremilast first launched, how was it positioned, and what do we understand differently now?

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

When do bridge programs make the most clinical sense for patients?

When do bridge programs make the most clinical sense for patients?

How do you document treatment goals when requesting newer therapies?

How do you document treatment goals when requesting newer therapies?

How do you document medical necessity when disease severity seems borderline?

How do you document medical necessity when disease severity seems borderline?

What clinical language resonates most with payers during prior authorization review?

What clinical language resonates most with payers during prior authorization review?

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

What is the single most meaningful management decision that becomes clearer after genomic testing?

What is the single most meaningful management decision that becomes clearer after genomic testing?

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

What clinical details make an appeal letter more persuasive?

What clinical details make an appeal letter more persuasive?

What supporting materials help overturn a denial?

What supporting materials help overturn a denial?

When do you escalate from prior auth to formal appeal?

When do you escalate from prior auth to formal appeal?

What’s one documentation habit that consistently improves approvals?

What’s one documentation habit that consistently improves approvals?

How do you document steroid failure before prescribing ruxolitinib cream?

How do you document steroid failure before prescribing ruxolitinib cream?

What helps secure coverage for ruxolitinib in step therapy plans?

What helps secure coverage for ruxolitinib in step therapy plans?

What documentation details helps support approval for ruxolitinib cream?

What documentation details helps support approval for ruxolitinib cream?

Can EHR templates improve access for new therapies like ruxolitinib?

Can EHR templates improve access for new therapies like ruxolitinib?

What are common documentation mistakes that delay access to newer topicals?

What are common documentation mistakes that delay access to newer topicals?

What’s key to documenting steroid failure or intolerance clearly?

What’s key to documenting steroid failure or intolerance clearly?

How do you talk to patients when access issues delay treatment?

How do you talk to patients when access issues delay treatment?

What’s your top access tip for new clinicians balancing care and paperwork?

What’s your top access tip for new clinicians balancing care and paperwork?

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

What makes a sunscreen well formulated from both a clinician and patient perspective?

What makes a sunscreen well formulated from both a clinician and patient perspective?

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

What is Helioplex technology, and how does it improve stability and UV coverage?

What is Helioplex technology, and how does it improve stability and UV coverage?

Why does a higher SPF still matter in real-world use?

Why does a higher SPF still matter in real-world use?

What is your take on the role of antioxidants in photoprotection?

What is your take on the role of antioxidants in photoprotection?

What are your go-to strategies for improving sunscreen adherence in daily life?

What are your go-to strategies for improving sunscreen adherence in daily life?

Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage?

Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage?

Which common medications increase photosensitivity, and how should this shape your counseling?

Which common medications increase photosensitivity, and how should this shape your counseling?

How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin?

How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin?

Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery?

Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery?

What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection?

What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection?

Are there specific ingredients or technologies that help balance acne treatment with barrier preservation?

Are there specific ingredients or technologies that help balance acne treatment with barrier preservation?

What are hydrophobically modified polymers, and what role do they play in cleanser tolerability?

What are hydrophobically modified polymers, and what role do they play in cleanser tolerability?

What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them?

What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them?

What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology?

What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology?

How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier?

How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier?

What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies?

What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies?

What is the "retinol sandwich" method for managing acne?

What is the "retinol sandwich" method for managing acne?

What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg?

What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg?

In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU?

In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU?

How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately?

How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately?

When might you choose tirbanibulin over 5-FU for AK field therapy?

When might you choose tirbanibulin over 5-FU for AK field therapy?

How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy?

How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy?

How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life?

What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life?

What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk?

What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk?

How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis?

How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis?

What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches?

What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches?

Is home-based NB-UVB a challenge to prescribe for clinicians?

Is home-based NB-UVB a challenge to prescribe for clinicians?

What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device?

What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device?

What are the key benefits of home-based NB-UVB devices?

What are the key benefits of home-based NB-UVB devices?

Is home-based NB-UVB better suited for localized disease or widespread conditions?

Is home-based NB-UVB better suited for localized disease or widespread conditions?

Is home-based NB-UVB device setup difficult for patients?

Is home-based NB-UVB device setup difficult for patients?

How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists?

How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists?

How straightforward is the prescribing and enrollment process for at-home phototherapy?

How straightforward is the prescribing and enrollment process for at-home phototherapy?

Why has phototherapy declined in use, and are the main barriers clinical or logistical?

Why has phototherapy declined in use, and are the main barriers clinical or logistical?

What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit?

What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit?

What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy?

What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy?

What differentiates IL-13 from IL-4 in the progression of AD?

What differentiates IL-13 from IL-4 in the progression of AD?

How do you identify and manage itch-dominant AD patients?

How do you identify and manage itch-dominant AD patients?

How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools?

How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools?

What role does proactive vs reactive therapy play in maintaining long-term disease control in AD?

What role does proactive vs reactive therapy play in maintaining long-term disease control in AD?

What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD?

What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD?

What are the long-term impacts of early-onset AD on child development and overall health?

What are the long-term impacts of early-onset AD on child development and overall health?

Should patients with moderate AD by treated with systemic therapies earlier in disease progression?

Should patients with moderate AD by treated with systemic therapies earlier in disease progression?

How can dermatologists identify and manage treatment resistance in patients with AD?

How can dermatologists identify and manage treatment resistance in patients with AD?

What are the most effective ways to communicate realistic treatment expectations to patients with AD?

What are the most effective ways to communicate realistic treatment expectations to patients with AD?

What challenges exist in assessing AD in patients with skin of color, and how can they be addressed?

What challenges exist in assessing AD in patients with skin of color, and how can they be addressed?

Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab?

Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab?

Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options?

Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options?

How can dermatologists improve diagnostic accuracy for AD in skin of color?

How can dermatologists improve diagnostic accuracy for AD in skin of color?

What clinical features define an ideal patient profile for starting lebrikizumab?

Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve?

Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve?

Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy?

Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy?

What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids?

What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids?

What results were seen in the clinical trials for lebrikizumab regarding itch reduction?

What results were seen in the clinical trials for lebrikizumab regarding itch reduction?

What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab?

What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab?

What outcomes have been observed with monthly maintenance dosing of lebrikizumab?

What outcomes have been observed with monthly maintenance dosing of lebrikizumab?

How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment?

How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment?

What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment?

What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment?

How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis?

How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis?

What are the major subtypes of CHE, and how can they be differentiated in clinical practice?

What are the major subtypes of CHE, and how can they be differentiated in clinical practice?

When should dermatologists consider patch testing in patients with chronic hand eczema?

When should dermatologists consider patch testing in patients with chronic hand eczema?

What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology?

What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology?

How does delgocitinib differ mechanistically from other topical therapies used for CHE?

How does delgocitinib differ mechanistically from other topical therapies used for CHE?

How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream?

How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream?

What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation?

What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation?

Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of?

Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of?

Is routine lab monitoring required for patients on delgocitinib cream?

Is routine lab monitoring required for patients on delgocitinib cream?

Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns?

Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns?

What is the MyPath Melanoma test, and how does it work?

What is the MyPath Melanoma test, and how does it work?

What types of melanocytic lesions is the MyPath test best suited for?

What types of melanocytic lesions is the MyPath test best suited for?

What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?

What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?

What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?

What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?

Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?

Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

What are the limitations of GEP testing in melanoma diagnosis?

What are the limitations of GEP testing in melanoma diagnosis?

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

What is lebrikizumab's safety profile?

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

Understanding the i31-SLNB Score: Moving Beyond Population Risk

Understanding the i31-SLNB Score: Moving Beyond Population Risk

Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score

Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score

Where This Matters Most: Applying i31-SLNB in Clinical Practice

Where This Matters Most: Applying i31-SLNB in Clinical Practice

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

What are common patient questions or concerns about this type of genomic testing?

What are common patient questions or concerns about this type of genomic testing?

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

How has the 31-GEP test report evolved?

How has the 31-GEP test report evolved?

What are some of the barriers to adopting the i31-SLNB score in community dermatology practices?

What are some of the barriers to adopting the i31-SLNB score in community dermatology practices?

What is the long-term vision for GEP-guided melanoma staging?

What is the long-term vision for GEP-guided melanoma staging?

What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB?

What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB?

Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?

Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Can ruxolitinib for vitiligo be used with therapeutic biologics?

How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo?

How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo?

How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo?

How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo?

How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo?

How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo?

What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo?

What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo?

What are the most common causes of drug-induced vitiligo?

What are the most common causes of drug-induced vitiligo?

Can vitiligo spontaneously resolve?

Can vitiligo spontaneously resolve?

How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo?

How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo?

How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne?

How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne?

How effective is sarecycline for managing truncal acne?

How effective is sarecycline for managing truncal acne?

Is sarecycline an appropriate option for pediatric and preteen patients with acne?

Is sarecycline an appropriate option for pediatric and preteen patients with acne?

What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics?

What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics?

Can sarecycline be combined with topical treatments or other systemic therapies?

Can sarecycline be combined with topical treatments or other systemic therapies?

How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship?

How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship?

Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne?

Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne?

What are the latest insights into the impact of hormonal fluctuations on acne severity?

What are the latest insights into the impact of hormonal fluctuations on acne severity?

How should dermatologists determine when to escalate from topical to systemic acne treatments?

How should dermatologists determine when to escalate from topical to systemic acne treatments?

How should acne treatments be adjusted for patients with sensitive or atopic skin?

How should acne treatments be adjusted for patients with sensitive or atopic skin?

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

What is the relationship between itch improvement and overall AD control?

What is the relationship between itch improvement and overall AD control?

What is the role of IL-13 in driving itch in AD?

What is the role of IL-13 in driving itch in AD?

How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification?

How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification?

Why aren’t more patients with moderate AD treated with advanced systemic therapies?

Why aren’t more patients with moderate AD treated with advanced systemic therapies?

How can dermatologists decide when to escalate to a systemic therapy for a patient with AD?

How can dermatologists decide when to escalate to a systemic therapy for a patient with AD?

What are the expected timelines for clinical improvement when initiating systemic therapies for AD?

What are the expected timelines for clinical improvement when initiating systemic therapies for AD?

How do you educate patients about the chronic nature of AD to improve adherence?

How do you educate patients about the chronic nature of AD to improve adherence?

How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence?

How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence?

How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD?

How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD?

What conditions should be considered in the clinical differential diagnosis of vitiligo?

What conditions should be considered in the clinical differential diagnosis of vitiligo?

What is the epidemiology of vitiligo?

What is the epidemiology of vitiligo?

What is the role of inflammation in the pathogenesis of vitiligo?

What is the role of inflammation in the pathogenesis of vitiligo?

How can patients with vitiligo get involved in support groups?

How can patients with vitiligo get involved in support groups?

What is the Koebner phenomenon in vitiligo?

What is the Koebner phenomenon in vitiligo?

What are some dermatologic syndromes that present with vitiligo?

What are some dermatologic syndromes that present with vitiligo?

What are some rare clinical subtypes of vitiligo?

What are some rare clinical subtypes of vitiligo?

How can vitiligo be distinguished from contact leukoderma?

How can vitiligo be distinguished from contact leukoderma?

Is it common for patients with vitiligo to have other autoimmune diseases?

Is it common for patients with vitiligo to have other autoimmune diseases?

Can vitiligo be treated with surgical intervention?

Can vitiligo be treated with surgical intervention?

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation?

Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation?

Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely?

Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely?

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Can ruxolitinib for vitiligo be used with therapeutic biologics?

How do comorbidities affect the decision to prescribe ruxolitinib for vitiligo?

How do comorbidities affect the decision to prescribe ruxolitinib for vitiligo?

Are there any benefits to using ruxolitinib in combination with narrowband UVB for vitiligo?

Are there any benefits to using ruxolitinib in combination with narrowband UVB for vitiligo?

How does repigmentation progress over time with ruxolitinib treatment?

How does repigmentation progress over time with ruxolitinib treatment?

Are there any emerging technologies or diagnostic tools that can enhance the early detection of vitiligo?

Are there any emerging technologies or diagnostic tools that can enhance the early detection of vitiligo?

What is the outlook on microneedling for vitiligo?

What is the outlook on microneedling for vitiligo?

What are some of the dermoscopic features of vitiligo?

What are some of the dermoscopic features of vitiligo?

Is there any long-term safety data available for lebrikizumab?

Is there any long-term safety data available for lebrikizumab?

How long should patients remain on lebrikizumab to achieve optimal long-term control of their atopic dermatitis symptoms?

How long should patients remain on lebrikizumab to achieve optimal long-term control of their atopic dermatitis symptoms?

Is lebrikizumab appropriate for patients who have failed other biologics?

Is lebrikizumab appropriate for patients who have failed other biologics?

Did any patients in clinical trials for lebrikizumab achieve EASI90?

Did any patients in clinical trials for lebrikizumab achieve EASI90?

How does lebrikizumab fit into proactive vs reactive AD treatment approaches?

How does lebrikizumab fit into proactive vs reactive AD treatment approaches?

Should lebrikizumab be used as monotherapy or can it be combined with other treatments?

Should lebrikizumab be used as monotherapy or can it be combined with other treatments?

What are the practical considerations for incorporating lebrikizumab into long-term treatment plans?

What are the practical considerations for incorporating lebrikizumab into long-term treatment plans?

What is the importance of early intervention in preventing disease progression in atopic dermatitis?

What is the importance of early intervention in preventing disease progression in atopic dermatitis?

$How should dermatologists sequence topical and systemic treatments in patients with refractory atopic dermatitis?$

How should dermatologists sequence topical and systemic treatments in patients with refractory atopic dermatitis?

How can dermatologists tailor treatment plans for patients with frequent infections related to atopic dermatitis?

How can dermatologists tailor treatment plans for patients with frequent infections related to atopic dermatitis?

Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors?

Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors?

How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo?

How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo?

Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types?

Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types?

What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo?

What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo?

How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo?

How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo?

What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo?

What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo?

Is there a risk of systemic absorption with ruxolitinib for vitiligo?

Is there a risk of systemic absorption with ruxolitinib for vitiligo?

What are some therapies that are currently in the pipeline for the treatment of vitiligo?

What are some therapies that are currently in the pipeline for the treatment of vitiligo?

What are the emerging therapies or treatment modalities being investigated for vitiligo?

What are the emerging therapies or treatment modalities being investigated for vitiligo?

How can dermatologists support patients in managing the psychological impacts of living with vitiligo?

How can dermatologists support patients in managing the psychological impacts of living with vitiligo?

What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management?

What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management?

What is the DecisionDx Melanoma test, and how does it work?

What is the DecisionDx Melanoma test, and how does it work?

The Questions We’re Really Trying to Answer in Early Melanoma

The Questions We’re Really Trying to Answer in Early Melanoma

Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria?

Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria?

How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients?

How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients?

How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility?

How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility?

How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients?

How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients?

What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed?

What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed?

How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes?

How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes?

What clinical and pathological features most significantly impact melanoma prognosis?

What clinical and pathological features most significantly impact melanoma prognosis?

With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers?

With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers?

Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face?

Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face?

How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials?

How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials?

Are skin reactions common with tirbanibulin ointment, and when do they typically peak?

Are skin reactions common with tirbanibulin ointment, and when do they typically peak?

What strategies can dermatologists use to manage common side effects associated with tirbanibulin ointment?

What strategies can dermatologists use to manage common side effects associated with tirbanibulin ointment?

How does tirbanibulin ointment's efficacy compare with other field-directed therapies for actinic keratosis?

How does tirbanibulin ointment's efficacy compare with other field-directed therapies for actinic keratosis?

What is the recommended dosing regimen for tirbanibulin ointment, and how does it differ from other field therapies?

What is the recommended dosing regimen for tirbanibulin ointment, and how does it differ from other field therapies?

What are the key risk factors for developing actinic keratosis, and how can dermatologists identify high-risk patients?

What are the key risk factors for developing actinic keratosis, and how can dermatologists identify high-risk patients?

Why is it important to address actinic keratosis as a chronic condition rather than isolated lesions?

Why is it important to address actinic keratosis as a chronic condition rather than isolated lesions?

What are the most effective strategies for preventing actinic keratosis in at-risk populations?

What are the most effective strategies for preventing actinic keratosis in at-risk populations?

What were the key results from the ADORING 1 and ADORING 2 pivotal trials for tapinarof in terms of efficacy?

What were the key results from the ADORING 1 and ADORING 2 pivotal trials for tapinarof in terms of efficacy?

How effective is tapinarof in reducing itch for patients with atopic dermatitis?

How effective is tapinarof in reducing itch for patients with atopic dermatitis?

What is the safety profile of tapinarof for atopic dermatitis?

What are the most common adverse effects observed with tapinarof for atopic dermatitis?

What are the most common adverse effects observed with tapinarof for atopic dermatitis?

How does tapinarof’s unique mechanism of action impact the disease course of atopic dermatitis?

How does tapinarof’s unique mechanism of action impact the disease course of atopic dermatitis?

What role does tapinarof play in restoring skin barrier function in atopic dermatitis?

What role does tapinarof play in restoring skin barrier function in atopic dermatitis?

How does tapinarof differ mechanistically from other topical treatments for atopic dermatitis?

How does tapinarof differ mechanistically from other topical treatments for atopic dermatitis?

What is your approach when counseling a patient who has experienced multiple AD treatment failures?

What is your approach when counseling a patient who has experienced multiple AD treatment failures?

How do you counsel patients with atopic dermatitis on reducing the risk of skin infection?

How do you counsel patients with atopic dermatitis on reducing the risk of skin infection?

How does skin barrier dysfunction contribute to the pathogenesis of atopic dermatitis?

How does skin barrier dysfunction contribute to the pathogenesis of atopic dermatitis?

What considerations should be taken when transitioning a patient from another biologic to lebrikizumab?

What considerations should be taken when transitioning a patient from another biologic to lebrikizumab?

How well does lebrikizumab maintain remission in patients who have achieved clear or almost clear skin?

How well does lebrikizumab maintain remission in patients who have achieved clear or almost clear skin?

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

How does the skin microbiome differ in patients with atopic dermatitis compared to healthy controls?

How does the skin microbiome differ in patients with atopic dermatitis compared to healthy controls?

Is there any clinical evidence to support the role of probiotics and prebiotics in managing atopic dermatitis?

Is there any clinical evidence to support the role of probiotics and prebiotics in managing atopic dermatitis?

What are the latest updates on the role of IL-4 and IL-13 in the pathogenesis of atopic dermatitis?

What are the latest updates on the role of IL-4 and IL-13 in the pathogenesis of atopic dermatitis?

Does ritlecitinib interact with vaccines, and should vaccination schedules be adjusted for patients on ritlecitinib?

Does ritlecitinib interact with vaccines, and should vaccination schedules be adjusted for patients on ritlecitinib?

What impact does ritlecitinib’s dual inhibition of JAK and TEC pathways have on the immune response in alopecia areata?

What impact does ritlecitinib’s dual inhibition of JAK and TEC pathways have on the immune response in alopecia areata?

How important is patient adherence when using ritlecitinib, and how can dermatologists encourage it?

How important is patient adherence when using ritlecitinib, and how can dermatologists encourage it?

What level of efficacy is seen in adolescent patients vs the overall population of patients on ritlecitinib?

What level of efficacy is seen in adolescent patients vs the overall population of patients on ritlecitinib?

What should patients do if they miss a dose of ritlecitinib?

What should patients do if they miss a dose of ritlecitinib?

What ongoing monitoring is recommended for patients taking ritlecitinib?

What ongoing monitoring is recommended for patients taking ritlecitinib?

What are the most common lab abnormalities observed in patients with ritlecitinib?

What are the most common lab abnormalities observed in patients with ritlecitinib?

How often does alopecia areata present in conjunction with nail changes, and how can this aid diagnosis?

How often does alopecia areata present in conjunction with nail changes, and how can this aid diagnosis?

What are the key points for educating patients about alopecia areata and its management?

What are the key points for educating patients about alopecia areata and its management?

What psychological support or resources can be provided to patients with alopecia areata?

What psychological support or resources can be provided to patients with alopecia areata?

How does lebrikizumab perform in treating difficult-to-manage areas like the face and hands in atopic dermatitis?

How does lebrikizumab perform in treating difficult-to-manage areas like the face and hands in atopic dermatitis?

Who is a good candidate for lebrikizumab?

Who is a good candidate for lebrikizumab?

What is the dosing regimen for lebrikizumab?

What is the dosing regimen for lebrikizumab?

What is the safety profile of lebrikizumab?

How does lebrikizumab impact the quality of life in patients with moderate to severe atopic dermatitis?

How does lebrikizumab impact the quality of life in patients with moderate to severe atopic dermatitis?

Should lebrikizumab be used as monotherapy, or can it be combined with other treatments?

Should lebrikizumab be used as monotherapy, or can it be combined with other treatments?

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab?

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab?

What are the criteria for assessing the severity of atopic dermatitis, and how does this influence treatment decisions?

What are the criteria for assessing the severity of atopic dermatitis, and how does this influence treatment decisions?

What are the best strategies for treating atopic dermatitis in sensitive areas, such as the face or eyelids?

What are the best strategies for treating atopic dermatitis in sensitive areas, such as the face or eyelids?

What are the key considerations for using systemic corticosteroids in severe cases of atopic dermatitis?

What are the key considerations for using systemic corticosteroids in severe cases of atopic dermatitis?

How do you manage expectations for patients beginning treatment with ritlecitinib?

How do you manage expectations for patients beginning treatment with ritlecitinib?

What specific patient populations benefit the most from ritlecitinib treatment?

What specific patient populations benefit the most from ritlecitinib treatment?

Can ritlecitinib be used in all subtypes of alopecia areata?

Can ritlecitinib be used in all subtypes of alopecia areata?

What is the recommended duration of treatment with ritlecitinib for alopecia areata?

What is the recommended duration of treatment with ritlecitinib for alopecia areata?

Can ritlecitinib be used as monotherapy, or can it be combined with other therapies for optimal results?

Can ritlecitinib be used as monotherapy, or can it be combined with other therapies for optimal results?

What is the role of ritlecitinib in maintenance therapy for patients with alopecia areata who have achieved hair regrowth?

What is the role of ritlecitinib in maintenance therapy for patients with alopecia areata who have achieved hair regrowth?

How does ritlecitinib compare to topical treatments for alopecia areata?

How does ritlecitinib compare to topical treatments for alopecia areata?

Are there any environmental factors that can trigger or exacerbate alopecia areata?

Are there any environmental factors that can trigger or exacerbate alopecia areata?

How do you address the emotional impact of alopecia areata on patients, particularly younger individuals?

How do you address the emotional impact of alopecia areata on patients, particularly younger individuals?

How does the severity of alopecia areata influence treatment decisions?

How does the severity of alopecia areata influence treatment decisions?

How should dermatologists manage missed doses of lebrikizumab with patients?

How should dermatologists manage missed doses of lebrikizumab with patients?

What are the most common adverse effects observed with lebrikizumab?

What are the most common adverse effects observed with lebrikizumab?

Are there any specific monitoring parameters that dermatologists should follow during treatment with lebrikizumab?

Are there any specific monitoring parameters that dermatologists should follow during treatment with lebrikizumab?

How quickly can patients expect to see improvement in their AD symptoms with lebrikizumab?

How quickly can patients expect to see improvement in their AD symptoms with lebrikizumab?

What can patients with atopic dermatitis expect in terms of long-term efficacy and sustained symptom control with lebrikizumab treatment?

What can patients with atopic dermatitis expect in terms of long-term efficacy and sustained symptom control with lebrikizumab treatment?

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

In what ways can dermatologists customize treatment plans when prescribing lebrikizumab?

How can dermatologists effectively position lebrikizumab as a treatment option to patients with atopic dermatitis, considering the variety of other available therapies?

How can dermatologists effectively position lebrikizumab as a treatment option to patients with atopic dermatitis, considering the variety of other available therapies?

How should dermatologists manage atopic dermatitis during pregnancy and breastfeeding?

How should dermatologists manage atopic dermatitis during pregnancy and breastfeeding?

How should dermatologists approach itch management in patients with severe pruritus due to atopic dermatitis?

How should dermatologists approach itch management in patients with severe pruritus due to atopic dermatitis?

Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

What are the considerations for using ixekizumab in patients with a history of serious infections?

What are the considerations for using ixekizumab in patients with a history of serious infections?

Does patient weight impact the dosing and efficacy of ixekizumab?

Does patient weight impact the dosing and efficacy of ixekizumab?

What strategies can be used to taper ixekizumab in patients with sustained remission?

What strategies can be used to taper ixekizumab in patients with sustained remission?

Can ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?

Can ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?

Should ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?

Should ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?

Are there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?

Are there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?

What factors contribute to the progression from mild to severe psoriasis?

What factors contribute to the progression from mild to severe psoriasis?

How can early intervention impact the long-term course of psoriasis?

How can early intervention impact the long-term course of psoriasis?

How can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?

How can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?

How does ixekizumab impact cardiovascular risk factors in patients with psoriasis?

How does ixekizumab impact cardiovascular risk factors in patients with psoriasis?

What are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?

What are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?

How does ixekizumab influence the risk of infections in patients with psoriasis?

How does ixekizumab influence the risk of infections in patients with psoriasis?

Is there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?

Is there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?

Is there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?

Is there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?

What lifestyle modifications should be recommended to patients receiving ixekizumab?

What lifestyle modifications should be recommended to patients receiving ixekizumab?

What is the recommended monitoring for patients with psoriasis receiving ixekizumab?

What is the recommended monitoring for patients with psoriasis receiving ixekizumab?

What is the role of biopsy in confirming a diagnosis of psoriasis?

What is the role of biopsy in confirming a diagnosis of psoriasis?

What role do patient preferences play in selecting a psoriasis treatment regimen?

What role do patient preferences play in selecting a psoriasis treatment regimen?

How do you address patient concerns about the long-term use of biologics?

How do you address patient concerns about the long-term use of biologics?

Can ritlecitinib be used in combination with topical treatments for alopecia areata?

Can ritlecitinib be used in combination with topical treatments for alopecia areata?

Are there any notable drug interactions seen with ritlecitinib?

Are there any notable drug interactions seen with ritlecitinib?

Can ritlecitinib be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants?

Can ritlecitinib be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants?

What is the mechanism of action of ritlecitinib?

What is the mechanism of action of ritlecitinib?

Who is the ideal patient for ritlecitinib, and are there any notable exclusions?

Who is the ideal patient for ritlecitinib, and are there any notable exclusions?

What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib?

What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib?

What is the recommended dosing regimen for ritlecitinib?

What is the recommended dosing regimen for ritlecitinib?

What is your approach for managing nonresponders or partial responders to ritlecitinib in patients with alopecia areata?

What is your approach for managing nonresponders or partial responders to ritlecitinib in patients with alopecia areata?

Can alopecia areata present with atypical or unusual clinical features?

Can alopecia areata present with atypical or unusual clinical features?

What is the significance of immune privilege in the pathogenesis of alopecia areata?

What is the significance of immune privilege in the pathogenesis of alopecia areata?

What is the likelihood of spontaneous hair regrowth in patients with alopecia areata?

What is the likelihood of spontaneous hair regrowth in patients with alopecia areata?

Should baricitinib be considered as a first-line therapy for alopecia areata?

Should baricitinib be considered as a first-line therapy for alopecia areata?

How does the safety profile of baricitinib compare to systemic corticosteroids in the treatment of alopecia areata?

Should therapy be stopped in patients who experience infectious events while on baricitinib?

Should therapy be stopped in patients who experience infectious events while on baricitinib?

How do you manage expectations for patients beginning treatment with baricitinib?

How do you manage expectations for patients beginning treatment with baricitinib?

Are there any specific counseling points that dermatologists should discuss with patients before starting baricitinib therapy for alopecia areata?

Are there any specific counseling points that dermatologists should discuss with patients before starting baricitinib therapy for alopecia areata?

What is the recommended approach for tapering or discontinuing baricitinib therapy in patients with alopecia areata who have achieved remission?

What is the recommended approach for tapering or discontinuing baricitinib therapy in patients with alopecia areata who have achieved remission?

Can baricitinib be used in different subtypes of alopecia areata?

Can baricitinib be used in different subtypes of alopecia areata?

How does the distribution pattern of hair loss influence treatment decisions in alopecia areata?

How does the distribution pattern of hair loss influence treatment decisions in alopecia areata?

What is the role of phototherapy in the treatment of alopecia areata?

What is the role of phototherapy in the treatment of alopecia areata?

How do you approach treatment in patients with primary cicatricial alopecia?

How do you approach treatment in patients with primary cicatricial alopecia?

What is the mechanism of action of lebrikizumab?

What is the mechanism of action of lebrikizumab?

What differentiates lebrikizumab from other IL-13 inhibitors for atopic dermatitis?

What differentiates lebrikizumab from other IL-13 inhibitors for atopic dermatitis?

What role can lebrikizumab play in steroid-sparing strategies for patients with atopic dermatitis?

What role can lebrikizumab play in steroid-sparing strategies for patients with atopic dermatitis?

What are the current recommendations for the use of lebrikizumab in pediatric atopic dermatitis patients?

What are the current recommendations for the use of lebrikizumab in pediatric atopic dermatitis patients?

Can patients treated with lebrikizumab receive live vaccines?

Can patients treated with lebrikizumab receive live vaccines?

What role does lebrikizumab play in managing chronic itch associated with atopic dermatitis?

What role does lebrikizumab play in managing chronic itch associated with atopic dermatitis?

Can lebrikizumab be used with topical corticosteroids or topical calcineurin inhibitors?

Can lebrikizumab be used with topical corticosteroids or topical calcineurin inhibitors?

How can dermatologists differentiate atopic dermatitis from other eczematous conditions?

How can dermatologists differentiate atopic dermatitis from other eczematous conditions?

What role does the skin microbiome play in the development and management of atopic dermatitis?

What role does the skin microbiome play in the development and management of atopic dermatitis?

How can dermatologists help patients manage the psychosocial impact of atopic dermatitis, including anxiety and depression?

How can dermatologists help patients manage the psychosocial impact of atopic dermatitis, including anxiety and depression?

What are the most common side effects associated with ixekizumab in long-term use?

What are the most common side effects associated with ixekizumab in long-term use?

How does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis?

How does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis?

How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?

How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?

Can ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach?

Can ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach?

Is there a need for loading doses when initiating ixekizumab therapy?

Is there a need for loading doses when initiating ixekizumab therapy?

How should dermatologists approach ixekizumab therapy in patients planning to conceive?

How should dermatologists approach ixekizumab therapy in patients planning to conceive?

What considerations should be made for elderly patients starting ixekizumab?

What considerations should be made for elderly patients starting ixekizumab?

What are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease?

What are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease?

How should dermatologists address concerns about injection-site reactions in patients starting ixekizumab?

How should dermatologists address concerns about injection-site reactions in patients starting ixekizumab?

How should psoriasis be managed in patients with a history of liver disease?

How should psoriasis be managed in patients with a history of liver disease?

What monitoring is essential for patients on long-term systemic psoriasis therapies?

What monitoring is essential for patients on long-term systemic psoriasis therapies?

What strategies can be used to improve patient adherence in psoriasis treatment regimens?

What strategies can be used to improve patient adherence in psoriasis treatment regimens?

What distinguishes the MOA of ritlecitinib from other JAK inhibitors?

What distinguishes the MOA of ritlecitinib from other JAK inhibitors?

Does patient age impact the effectiveness and safety of ritlecitinib?

Does patient age impact the effectiveness and safety of ritlecitinib?

How should patients be educated about the potential long-term outcomes of ritlecitinib therapy?

How should patients be educated about the potential long-term outcomes of ritlecitinib therapy?

How soon can patients with alopecia areata begin to see results on ritlecitinib?

How soon can patients with alopecia areata begin to see results on ritlecitinib?

How does ritlecitinib perform in patients with severe alopecia areata?

How does ritlecitinib perform in patients with severe alopecia areata?

What lab assessments are recommended prior to initiating ritlecitinib?

What lab assessments are recommended prior to initiating ritlecitinib?

What are the most common adverse reactions seen with ritlecitinib?

What are the most common adverse reactions seen with ritlecitinib?

What are some early signs and symptoms associated with alopecia areata?

What are some early signs and symptoms associated with alopecia areata?

Can dietary changes, lifestyle modifications, or supplements influence the course of alopecia areata?

Can dietary changes, lifestyle modifications, or supplements influence the course of alopecia areata?

How does the presence of comorbidities influence the management of alopecia areata?

How does the presence of comorbidities influence the management of alopecia areata?

How does the safety profile of ixekizumab compare to other IL-17 inhibitors?

How soon can patients on ixekizumab for psoriasis expect to see results?

How soon can patients on ixekizumab for psoriasis expect to see results?

Can ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis?

Can ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis?

Who is the ideal patient for ixekizumab, and are there any notable exclusions?

Who is the ideal patient for ixekizumab, and are there any notable exclusions?

What patient education points are important to convey to patients starting ixekizumab?

What patient education points are important to convey to patients starting ixekizumab?

Are there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab?

Are there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab?

Are there any head-to-head studies comparing ixekizumab to other biologics?

Are there any head-to-head studies comparing ixekizumab to other biologics?

Do patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis?

Do patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis?

What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?

What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?

How do you manage patients with psoriasis with concurrent inflammatory bowel disease?

How do you manage patients with psoriasis with concurrent inflammatory bowel disease?

What are the most common adverse reactions seen with ixekizumab?

What are the most common adverse reactions seen with ixekizumab?

What is the dosing regimen for ixekizumab?

What is the dosing regimen for ixekizumab?

What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?

What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?

Is ixekizumab safe for use in pediatric populations?

Is ixekizumab safe for use in pediatric populations?

What is the mechanism of action of ixekizumab?

What is the mechanism of action of ixekizumab?

When do you consider a biologic as a first-line treatment for psoriasis?

When do you consider a biologic as a first-line treatment for psoriasis?

What are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this?

What are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this?

What is your approach when counseling a patient who has experienced multiple treatment failures?

What is your approach when counseling a patient who has experienced multiple treatment failures?

What role does patient education play in improving adherence to psoriasis treatment regimens?

What role does patient education play in improving adherence to psoriasis treatment regimens?

How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment?

How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment?

Can ruxolitinib be used as a first-line treatment for vitiligo?

Can ruxolitinib be used as a first-line treatment for vitiligo?

Can ruxolitinib be used with phototherapy

Can ruxolitinib be used with phototherapy

What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo?

What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo?

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation

How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo?

How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo?

Are there any contraindications or precautions dermatologists should consider before beginning a patient on ruxolitinib for vitiligo?

Are there any contraindications or precautions dermatologists should consider before beginning a patient on ruxolitinib for vitiligo?

Is there any recommended monitoring for patients on ruxolitinib for vitiligo?

Is there any recommended monitoring for patients on ruxolitinib for vitiligo?

Is phototherapy effective in all types of vitiligo?

Is phototherapy effective in all types of vitiligo?

How soon should treatment be initiated after diagnosing vitiligo?

How soon should treatment be initiated after diagnosing vitiligo?

What factors should be considered when selecting treatment for pediatric patients with vitiligo?

What factors should be considered when selecting treatment for pediatric patients with vitiligo?

Can ruxolitinib for vitiligo be used intermittently?

Can ruxolitinib for vitiligo be used intermittently?

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation?

How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation?

How does ruxolitinib compare to other treatment options for vitiligo?

How does ruxolitinib compare to other treatment options for vitiligo?

Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?

Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?

Are there any patient support programs available for ruxolitinib for vitiligo?

Are there any patient support programs available for ruxolitinib for vitiligo?

What factors should be considered when determining if a patient is eligible for ruxolitinib for vitiligo?

What factors should be considered when determining if a patient is eligible for ruxolitinib for vitiligo?

Can ruxolitinib be used with phototherapy?

Can ruxolitinib be used with phototherapy?

What are some lesser-known comorbidities of vitiligo?

What are some lesser-known comorbidities of vitiligo?

What is the outlook on regenerative therapies for vitiligo?

What is the outlook on regenerative therapies for vitiligo?

What are some triggers that may exacerbate vitiligo?

What are some triggers that may exacerbate vitiligo?

Can ruxolitinib for vitiligo be used on sensitive skin areas (David Rosmarin, MA, MD)?

Can ruxolitinib for vitiligo be used on sensitive skin areas (David Rosmarin, MA, MD)?

What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo?

What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo?

What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo?

What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo?

Should ruxolitinib be used as a monotherapy or can it be combined with other treatments for vitiligo?

Should ruxolitinib be used as a monotherapy or can it be combined with other treatments for vitiligo?

How long should ruxolitinib treatment be continued for optimal results?

How long should ruxolitinib treatment be continued for optimal results?

Which parts of the body does ruxolitinib work best on?

Which parts of the body does ruxolitinib work best on?

Are there any drug interactions to consider when prescribing ruxolitinib for vitiligo?

Are there any drug interactions to consider when prescribing ruxolitinib for vitiligo?

What are some important comorbidities associated with vitiligo?

What are some important comorbidities associated with vitiligo?

How does ethnicity influence the presentation and management of vitiligo?

How does ethnicity influence the presentation and management of vitiligo?

How do you counsel patients with vitiligo about the need for sun protection?

How do you counsel patients with vitiligo about the need for sun protection?

What is the recommended dosing regimen for tapinarof?

What is the recommended dosing regimen for tapinarof?

Who is the ideal patient for tapinarof, and are there any notable exclusions?

Who is the ideal patient for tapinarof, and are there any notable exclusions?

What is the safety profile of tapinarof?

What is the mechanism of action of tapinarof?

What is the mechanism of action of tapinarof?

What should patients expect when they stop treatment with tapinarof?

What should patients expect when they stop treatment with tapinarof?

What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?

What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?

Is tapinarof well tolerated on sensitive skin areas?

Is tapinarof well tolerated on sensitive skin areas?

What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management?

What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management?

What are the latest advancements in understanding the pathogenesis of psoriasis?

What are the latest advancements in understanding the pathogenesis of psoriasis?

How do lifestyle factors like diet and stress impact your approach to psoriasis management?

How do lifestyle factors like diet and stress impact your approach to psoriasis management?

How do you counsel patients on quality of life impacts from psoriasis?

How do you counsel patients on quality of life impacts from psoriasis?

Who is the ideal patient for ruxolitinib for vitiligo?

Who is the ideal patient for ruxolitinib for vitiligo?

How do you set expectations with patients before starting them on ruxolitinib for vitiligo?

How do you set expectations with patients before starting them on ruxolitinib for vitiligo?

How quickly can patients expect to see results with ruxolitinib for vitiligo?

How quickly can patients expect to see results with ruxolitinib for vitiligo?

What is the safety profile of ruxolitinib for vitiligo?

Can ruxolitinib for vitiligo be used with other JAK inhibitors?

Can ruxolitinib for vitiligo be used with other JAK inhibitors?

What are the limitations of use for ruxolitinib for vitiligo?

What are the limitations of use for ruxolitinib for vitiligo?

What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo?

What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo?

How does your treatment approach differ in treating segmental vs nonsegmental vitiligo?

How does your treatment approach differ in treating segmental vs nonsegmental vitiligo?

What is the role of the JAK-STAT pathway in vitiligo?

What is the role of the JAK-STAT pathway in vitiligo?

How can dermatologists address challenges and disparities in access to vitiligo care?

How can dermatologists address challenges and disparities in access to vitiligo care?

What is the mechanism of action for ruxolitinib for vitiligo?

What is the mechanism of action for ruxolitinib for vitiligo?

Why is there a boxed warning for ruxolitinib for vitiligo?

Why is there a boxed warning for ruxolitinib for vitiligo?

What are the most common adverse reactions seen with ruxolitinib for vitiligo?

What are the most common adverse reactions seen with ruxolitinib for vitiligo?

What is the recommended dosing regimen for ruxolitinib for vitiligo?

What is the recommended dosing regimen for ruxolitinib for vitiligo?

Can ruxolitinib for vitiligo be used on sensitive skin areas?

Can ruxolitinib for vitiligo be used on sensitive skin areas?

What are some ways you set expectations with patients before starting them on ruxolitinib for vitiligo?

What are some ways you set expectations with patients before starting them on ruxolitinib for vitiligo?

Are there ways to treat vitiligo surgically?

Are there ways to treat vitiligo surgically?

What long-term management strategies do you recommend for patients with vitiligo?

What long-term management strategies do you recommend for patients with vitiligo?

How do you counsel patients with vitiligo on the dangers of unregulated skin lightening / bleaching creams?

How do you counsel patients with vitiligo on the dangers of unregulated skin lightening / bleaching creams?

What is the psychosocial impact of vitiligo?

What is the psychosocial impact of vitiligo?

What monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels?

What monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels?

How does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis?

How does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis?

Is bimekizumab effective for patients who have failed an IL-17 blocker?

Is bimekizumab effective for patients who have failed an IL-17 blocker?

Has the efficacy of bimekizumab been compared to other psoriasis medications?

Has the efficacy of bimekizumab been compared to other psoriasis medications?

What is the long-term safety data for bimekizumab?

What is the long-term safety data for bimekizumab?

What is the risk of suicidal ideation or behavior in patients taking bimekizumab?

What is the risk of suicidal ideation or behavior in patients taking bimekizumab?

Does bimekizumab have a boxed warning?

Does bimekizumab have a boxed warning?

How do you approach long-term management of plaque psoriasis?

How do you approach long-term management of plaque psoriasis?

What are some of the limitations of the current conventional clinical measures used to determine psoriasis severity?

What are some of the limitations of the current conventional clinical measures used to determine psoriasis severity?

What are some limitations of the older biologics for psoriasis?

What are some limitations of the older biologics for psoriasis?

How is cantharidin applied?

How is cantharidin applied?

On what areas of the body can cantharidin be applied?

On what areas of the body can cantharidin be applied?

What is the mechanism of action for cantharidin?

What is the mechanism of action for cantharidin?

Can you reuse the cantharidin applicator?

Can you reuse the cantharidin applicator?

Why is denatonium benzoate included in the ingredient list for cantharidin?

Why is denatonium benzoate included in the ingredient list for cantharidin?

What are some important instructions you should give to give patients being treated with cantharidin?

What are some important instructions you should give to give patients being treated with cantharidin?

Why are patients with atopic dermatitis more at risk of contracting molluscum contagiosum?

Why are patients with atopic dermatitis more at risk of contracting molluscum contagiosum?

What are some complications and long-term effects associated with molluscum contagiosum?

What are some complications and long-term effects associated with molluscum contagiosum?

What are some of the biggest challenges in treating molluscum contagiosum?

What are some of the biggest challenges in treating molluscum contagiosum?

What classification from the 40-GEP test would make you consider referral to a radiation oncologist and adjuvant radiation therapy?

What classification from the 40-GEP test would make you consider referral to a radiation oncologist and adjuvant radiation therapy?

Can the 40-GEP test be performed on superficial biopsies?

Can the 40-GEP test be performed on superficial biopsies?

How long does it take for a report to be delivered for the 40-GEP test?

How long does it take for a report to be delivered for the 40-GEP test?

Do you consider imaging for patients with class 2a or 2b results on the 40-GEP test?

Do you consider imaging for patients with class 2a or 2b results on the 40-GEP test?

How do accuracy metrics of the 40-GEP test compare with those of the AJCC8 and BWH?

How do accuracy metrics of the 40-GEP test compare with those of the AJCC8 and BWH?

How does the 40-GEP test influence your decision to use radiologic imaging to check regional lymph nodes and distant organs for metastasis?

How does the 40-GEP test influence your decision to use radiologic imaging to check regional lymph nodes and distant organs for metastasis?

What clinicopathologic factors have significant prognostic value?

What clinicopathologic factors have significant prognostic value?

How do you undertake a multidisciplinary approach to SCC management?

How do you undertake a multidisciplinary approach to SCC management?

What patient and disease characteristics do you consider when choosing a systemic therapy for patients with metastatic SCC?

What patient and disease characteristics do you consider when choosing a systemic therapy for patients with metastatic SCC?

How does the test inform the clinical management of patients with high-risk SCC?

How does the test inform the clinical management of patients with high-risk SCC?

Is there drug monitoring required for bimekizumab?

Is there drug monitoring required for bimekizumab?

What is the dosing regimen for bimekizumab?

What is the dosing regimen for bimekizumab?

Which patients are eligible for treatment with cantharidin, and are there any notable exclusions?

Which patients are eligible for treatment with cantharidin, and are there any notable exclusions?

What are some of the most common adverse reactions associated with cantharidin?

What are some of the most common adverse reactions associated with cantharidin?

Does cantharidin provide any benefits over other treatments for molluscum contagiosum?

Does cantharidin provide any benefits over other treatments for molluscum contagiosum?

How does the cantharidin applicator work?

How does the cantharidin applicator work?

Can other topical products be used after cantharidin application?

Can other topical products be used after cantharidin application?

What is the recommended dosing regimen for cantharidin?

What is the recommended dosing regimen for cantharidin?

What were the primary endpoints of the CAMP-1 and CAMP-2 trials?

What were the primary endpoints of the CAMP-1 and CAMP-2 trials?

What are some interesting facets of the pathophysiology of molluscum contagiosum?

What are some interesting facets of the pathophysiology of molluscum contagiosum?

How do you navigate concerns from parents of pediatric patients with molluscum contagiosum?

How do you navigate concerns from parents of pediatric patients with molluscum contagiosum?

Which patients are at higher risk of contracting molluscum contagiosum?

Which patients are at higher risk of contracting molluscum contagiosum?

What is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments?

What is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments?

What is the safety profile of bimekizumab and what are the most common adverse effects seen so far?

Who is eligible for treatment with bimekizumab? Are there any notable exclusion criteria?

Who is eligible for treatment with bimekizumab? Are there any notable exclusion criteria?

What is the mechanism of action for ruxolitinib topical cream?

What is the mechanism of action for ruxolitinib topical cream?

What strategies can you use to improve adherence with ruxolitinib?

What strategies can you use to improve adherence with ruxolitinib?

What is the benefit of ruxolitinib over topical calcineurin inhibitors?

What is the benefit of ruxolitinib over topical calcineurin inhibitors?

What is the benefit of ruxolitinib over topical corticosteroids?

What is the benefit of ruxolitinib over topical corticosteroids?

What is the benefit of ruxolitinib over topical PDE-4 inhibitors?

What is the benefit of ruxolitinib over topical PDE-4 inhibitors?

Can ruxolitinib be used intermittently as maintenance to reduce flares and relapse?

Can ruxolitinib be used intermittently as maintenance to reduce flares and relapse?

What were the notable results of the TRuE-AD clinical trials for topical ruxolitinib?

What were the notable results of the TRuE-AD clinical trials for topical ruxolitinib?

What are some considerations when diagnosing and treating atopic dermatitis in patients with skin of color?

What are some considerations when diagnosing and treating atopic dermatitis in patients with skin of color?

What are some of the unmet needs still remaining in the atopic dermatitis treatment landscape?

What are some of the unmet needs still remaining in the atopic dermatitis treatment landscape?

What maintenance therapy for atopic dermatitis do you recommend to patients?

What maintenance therapy for atopic dermatitis do you recommend to patients?

What is the recommended dosing regimen for clobetasol propionate cream 0.025%?

What is the recommended dosing regimen for clobetasol propionate cream 0.025%?

How does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream?

How does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream?

What makes the formulation of clobetasol propionate cream 0.025% unique?

What makes the formulation of clobetasol propionate cream 0.025% unique?

What is the recommended dosing regimen for betamethasone dipropionate spray 0.05%?

What is the recommended dosing regimen for betamethasone dipropionate spray 0.05%?

What are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis?

What are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis?

What areas of the body does betamethasone dipropionate spray 0.05% work best on?

What areas of the body does betamethasone dipropionate spray 0.05% work best on?

How important is the delivery vehicle when selecting a topical treatment for psoriasis?

How important is the delivery vehicle when selecting a topical treatment for psoriasis?

How do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis?

How do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis?

Do issues of accessibility affect your approach when considering treatment options for plaque psoriasis?

Do issues of accessibility affect your approach when considering treatment options for plaque psoriasis?

What place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically?

What place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically?

How do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis?

How do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis?

What are some of the limitations of topical steroids with respect to management of plaque psoriasis?

What are some of the limitations of topical steroids with respect to management of plaque psoriasis?

What are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals?

What are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals?

What limitations of other topical therapies does roflumilast address for patients with plaque psoriasis?

What limitations of other topical therapies does roflumilast address for patients with plaque psoriasis?

What clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis?

What clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis?

Can you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis?

Can you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis?

Can topical roflumilast be used in combination with systemic therapies?

Can topical roflumilast be used in combination with systemic therapies?

Is topical roflumilast safe and effective for long-term use?

Is topical roflumilast safe and effective for long-term use?

How would you describe the formulation/vehicle for topical roflumilast?

How would you describe the formulation/vehicle for topical roflumilast?

Now that there are more options to treat psoriasis, how do you choose when to use roflumilast?

Now that there are more options to treat psoriasis, how do you choose when to use roflumilast?

What is new and exciting for treating pediatric patients with plaque psoriasis?

What is new and exciting for treating pediatric patients with plaque psoriasis?

With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?

With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

How quickly does bimekizumab start working?

How quickly does bimekizumab start working?

Regarding oral candidiasis, how has this been managed and has it required discontinuation of the medication?

Regarding oral candidiasis, how has this been managed and has it required discontinuation of the medication?

Are there any support programs to help patients access bimekizumab?

Are there any support programs to help patients access bimekizumab?

Is baricitinib effective for patients with substantial eyebrow and eyelash loss?

Is baricitinib effective for patients with substantial eyebrow and eyelash loss?

Are there any support programs available for patients who are prescribed baricitinib?

Are there any support programs available for patients who are prescribed baricitinib?

Can baricitinib be used in combination with topical treatments?

Can baricitinib be used in combination with topical treatments?

How does the efficacy of baricitinib compare to topical and corticosteroid treatments?

How does the efficacy of baricitinib compare to topical and corticosteroid treatments?

What was the primary measure of efficacy in the 2 randomized double-blind clinical trials conducted on baricitinib?

What was the primary measure of efficacy in the 2 randomized double-blind clinical trials conducted on baricitinib?

What was the baseline SALT score for patients included in the BRAVE-AA1 and BRAVE-AA2 trials?

What was the baseline SALT score for patients included in the BRAVE-AA1 and BRAVE-AA2 trials?

When is baricitinib recommended for atopic dermatitis?

When is baricitinib recommended for atopic dermatitis?

Should baricitinib dosage be reduced when adequate response is achieved?

Should baricitinib dosage be reduced when adequate response is achieved?

Are results maintained after lowering the dosage or stoppage of baricitinib?

Are results maintained after lowering the dosage or stoppage of baricitinib?

Is long-term treatment necessary to observe maximal clinical benefit from baricitinib?

Is long-term treatment necessary to observe maximal clinical benefit from baricitinib?

What kind of monitoring is suggested for patients taking baricitinib?

What kind of monitoring is suggested for patients taking baricitinib?

Which patients are recommended for treatment with spesolimab, and are there any exclusions?

Which patients are recommended for treatment with spesolimab, and are there any exclusions?

What spesolimab-associated hypersensitivity reactions should patients be monitored for?

What spesolimab-associated hypersensitivity reactions should patients be monitored for?

Can patients treated with spesolimab receive live vaccines?

Can patients treated with spesolimab receive live vaccines?

What is the recommended dosing regimen for spesolimab?

What is the recommended dosing regimen for spesolimab?

What is the mechanism of action of spesolimab?

What is the mechanism of action of spesolimab?

How quickly can patients see the onset of pustular clearance after a spesolimab infusion?

How quickly can patients see the onset of pustular clearance after a spesolimab infusion?

What was the primary endpoint of the Effasayil trial?

What was the primary endpoint of the Effasayil trial?

The use, tapering, or stopping of which medications can be associated with GPP?

The use, tapering, or stopping of which medications can be associated with GPP?

What are some lesser-known risk factors of GPP?

What are some lesser-known risk factors of GPP?

What are some of the biggest challenges in treating GPP?

What are some of the biggest challenges in treating GPP?

What are some patient examples you’ve had success with using topical roflumilast?

What are some patient examples you’ve had success with using topical roflumilast?

How does the formulation of roflumilast differ from other topicals?

How does the formulation of roflumilast differ from other topicals?

What properties of roflumilast allow it to follow a once-daily dosing regimen?

What properties of roflumilast allow it to follow a once-daily dosing regimen?

What is the mechanism of action of roflumilast?

What is the mechanism of action of roflumilast?

Do patients using roflumilast experience stinging and burning?

Do patients using roflumilast experience stinging and burning?

Are there any limitations on duration of use with roflumilast?

Are there any limitations on duration of use with roflumilast?

Who is the ideal patient for roflumilast?

Who is the ideal patient for roflumilast?

What does the long-term safety and durability profile look like for roflumilast?

Does roflumilast continue to be effective over a long period of time?

Does roflumilast continue to be effective over a long period of time?

Has the emergence of new topical options affected the course of treatment you select for your patients?

Has the emergence of new topical options affected the course of treatment you select for your patients?

What are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis?

What are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis?

How have the emergence of nonsteroidal topical options in recent years impacted your practice?

How have the emergence of nonsteroidal topical options in recent years impacted your practice?

How do you foresee the 40-GEP test contributing to standard of care for SCC?

How do you foresee the 40-GEP test contributing to standard of care for SCC?

What risk factors relating to history and physical examination would make a patient with SCC a good candidate for the 40-GEP test?

What risk factors relating to history and physical examination would make a patient with SCC a good candidate for the 40-GEP test?

What surgical and pathological findings would make a patient with SCC a good candidate for the 40-GEP test?

What surgical and pathological findings would make a patient with SCC a good candidate for the 40-GEP test?

Is an additional procedure needed to collect a specimen for the 40-GEP test?

Is an additional procedure needed to collect a specimen for the 40-GEP test?

What classification from the 40-GEP test would make you consider baseline radiologic imaging?

What classification from the 40-GEP test would make you consider baseline radiologic imaging?

What classification from the 40-GEP test would make you consider sentinel lymph node biopsy?

What classification from the 40-GEP test would make you consider sentinel lymph node biopsy?

Are there any patient access programs available for the 40-GEP test?

Are there any patient access programs available for the 40-GEP test?

Which class is the best predictor of metastasis with regard to the 40-GEP test?

Which class is the best predictor of metastasis with regard to the 40-GEP test?

What are some lesser-known factors that can increase the risk of developing SCC?

What are some lesser-known factors that can increase the risk of developing SCC?

How can we better educate our patients on minimizing the risk of developing SCC?

How can we better educate our patients on minimizing the risk of developing SCC?

What is the connection between calcineurin inhibitors and SCC development and progression?

What is the connection between calcineurin inhibitors and SCC development and progression?

Why do organ transplant recipients have a higher risk of developing SCC?

Why do organ transplant recipients have a higher risk of developing SCC?

What is the 40-GEP test?

What is the 40-GEP test?

In what ways can alopecia areata affect quality of life?

In what ways can alopecia areata affect quality of life?

How can I identify patients who would benefit from ruxolitinib cream?

How can I identify patients who would benefit from ruxolitinib cream?

What is the clinical presentation of GPP?

What is the clinical presentation of GPP?

Why do we need to better assess SCC prognosis?

Why do we need to better assess SCC prognosis?

How does the 40-GEP test work?

How does the 40-GEP test work?

What SCCs are appropriate for the 40-GEP test?

What SCCs are appropriate for the 40-GEP test?

How do you discuss 40-GEP test results with patients?

How do you discuss 40-GEP test results with patients?

Is the 40-GEP test covered by Medicare?

Is the 40-GEP test covered by Medicare?

Why doesn't SCC get the respect it should?

Why doesn't SCC get the respect it should?

What are the traditional SCC prognostic paradigms?

What are the traditional SCC prognostic paradigms?

What are the trends in US incidence of SCC?

What are the trends in US incidence of SCC?

Who is the ideal patient for the 40-GEP test?

Who is the ideal patient for the 40-GEP test?

Are patients with alopecia areata more likely to have other dermatologic conditions?

Are patients with alopecia areata more likely to have other dermatologic conditions?

What was the ORAL Surveillance study, and how does it relate to the labeling language of Olumiant?

What was the ORAL Surveillance study, and how does it relate to the labeling language of Olumiant?

Which patients are eligible for treatment with baricitinib and are there any notable exclusion criteria?

Which patients are eligible for treatment with baricitinib and are there any notable exclusion criteria?

How soon can patients start seeing results on baricitinib?

How soon can patients start seeing results on baricitinib?

What is the mechanism of action of baricitinib?

What is the mechanism of action of baricitinib?

How does the mechanism of action of baricitinib differ from topical JAK inhibitors?

How does the mechanism of action of baricitinib differ from topical JAK inhibitors?

Can baricitinib be used in combination with other biologics, JAK inhibitors, or immunosuppressants?

Can baricitinib be used in combination with other biologics, JAK inhibitors, or immunosuppressants?

What is the recommended dosing regimen for baricitinib?

What is the recommended dosing regimen for baricitinib?

Is there any long-term safety data available for baricitinib?

Is there any long-term safety data available for baricitinib?

Can ruxolitinib cream be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants?

Can ruxolitinib cream be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants?

What limitations of other atopic dermatitis therapies does ruxolitinib cream address?

What limitations of other atopic dermatitis therapies does ruxolitinib cream address?

How quickly can patients expect to start feeling itch reduction with ruxolitinib cream?

How quickly can patients expect to start feeling itch reduction with ruxolitinib cream?

Ruxolitinib cream is indicated for short-term use; when should patients discontinue use?

Ruxolitinib cream is indicated for short-term use; when should patients discontinue use?

What is the recommended dosing regimen for ruxolitinib cream?

What is the recommended dosing regimen for ruxolitinib cream?

What is the maximum dosage per week recommended for ruxolitinib cream?

What is the maximum dosage per week recommended for ruxolitinib cream?

When do you recommend the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare?

When do you recommend the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare?

When should oral antibiotics be used in the treatment of atopic dermatitis?

When should oral antibiotics be used in the treatment of atopic dermatitis?

What do you recommend for patients with atopic dermatitis who require long-term treatment?

What do you recommend for patients with atopic dermatitis who require long-term treatment?

Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA?

Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA?

$If a patient is on long term prednisone from PCP for refractory AD can that patient also start a JAK?$

If a patient is on long term prednisone from PCP for refractory AD can that patient also start a JAK?

Any concern using topical JAK inhibitors in patients on dupilumab?

Any concern using topical JAK inhibitors in patients on dupilumab?

Do new topicals address underlying systemic inflammation?

Do new topicals address underlying systemic inflammation?

Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD?

Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD?

Do you recommend getting the zoster vaccine before starting a JAK inhibitor?

Do you recommend getting the zoster vaccine before starting a JAK inhibitor?

Can tapinarof be used in pregnant patients with psoriasis?

Can tapinarof be used in pregnant patients with psoriasis?

Roflumilast vs tapinarof - which is more efficacious?

Roflumilast vs tapinarof - which is more efficacious?

What is the best treatment for lichen planus pigmentosus?

What is the best treatment for lichen planus pigmentosus?

How has the 40-GEP test been used by my colleagues?

How has the 40-GEP test been used by my colleagues?

What is the success rate of tralokinumab in patients who have failed dupilumab?

What is the success rate of tralokinumab in patients who have failed dupilumab?

How quickly do patients experience clearance results with topical roflumilast?

How quickly do patients experience clearance results with topical roflumilast?

How would you describe the overall tolerability of topical roflumilast?

How would you describe the overall tolerability of topical roflumilast?

What is the long-term safety and efficacy data of topical roflumilast?

What is the long-term safety and efficacy data of topical roflumilast?

How has topical roflumilast simplified the way you consult patients with plaque psoriasis?

How has topical roflumilast simplified the way you consult patients with plaque psoriasis?

How would you present the product profile of topical roflumilast to HCP colleagues who are reluctant due to poor prior experience with other PDE4 inhibitors?

When it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids?

When it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids?

What are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids?

What are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids?

How do you approach management of plaque psoriasis in challenging sensitive areas?

How do you approach management of plaque psoriasis in challenging sensitive areas?

How important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments?

How important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments?

When augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through?

When augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through?

What is Generalized Pustular Psoriasis (GPP)?

What is Generalized Pustular Psoriasis (GPP)?

What are some of the systemic associations of acute GPP?

What are some of the systemic associations of acute GPP?

Who is at risk for GPP?

Who is at risk for GPP?

What are some known triggers of GPP?

What are some known triggers of GPP?

What is the pathophysiology of GPP?

What is the pathophysiology of GPP?

How does the pathophysiology in GPP differ from plaque type psoriasis?

How does the pathophysiology in GPP differ from plaque type psoriasis?

When evaluating a patient with suspected GPP, what other entities does one need to exclude?

When evaluating a patient with suspected GPP, what other entities does one need to exclude?

What are some of the common laboratory abnormalities associated with GPP?

What are some of the common laboratory abnormalities associated with GPP?

What are treatment options for GPP?

What are treatment options for GPP?

What is the safety profile for spesolimab?

What ingredients do you like to see in the products you use to treat plaque psoriasis?

What ingredients do you like to see in the products you use to treat plaque psoriasis?

How important are vehicles in topical Plaque Psoriasis therapy?

How important are vehicles in topical Plaque Psoriasis therapy?

What common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients?

What common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients?

Should we really care about systemic safety when treating Plaque Psoriasis with topical therapies?

Should we really care about systemic safety when treating Plaque Psoriasis with topical therapies?

How important is continuity of care for topical plaque psoriasis therapy?

How important is continuity of care for topical plaque psoriasis therapy?

How much time does your staff have to spend gaining patient access to medication for plaque psoriasis?

How much time does your staff have to spend gaining patient access to medication for plaque psoriasis?

How do you utilize product samples in plaque psoriasis?

How do you utilize product samples in plaque psoriasis?

How do access, tolerability and efficacy improve compliance?

How do access, tolerability and efficacy improve compliance?

Which patients fit the profile for combination therapy of Biologics and topical treatment in Plaque Psoriasis?

How do you address compliance with your patients in topical treatment of plaque psoriasis?

How do you address compliance with your patients in topical treatment of plaque psoriasis?

What are high risk features of cSCC?

What are high risk features of cSCC?

What is the best sunscreen to prevent skin cancer?

What is the best sunscreen to prevent skin cancer?

Is SCC more deadly than melanoma?

Is SCC more deadly than melanoma?

How do I order the 40-GEP test?

How do I order the 40-GEP test?

Should I consider the 40-GEP test in lower risk patients?

Should I consider the 40-GEP test in lower risk patients?

Which patients should be considered for the 40-GEP test?

Which patients should be considered for the 40-GEP test?

Why has the 40-GEP test been validated on several data sets?

Why has the 40-GEP test been validated on several data sets?

How was the 40-GEP test developed?

How was the 40-GEP test developed?

How do GEP tests work?

How do GEP tests work?

Why should you consider treating the chin with fillers when considering lip augmentation?

Why should you consider treating the chin with fillers when considering lip augmentation?

Botox for the neck: where do you start and how many units do you recommend?

Botox for the neck: where do you start and how many units do you recommend?

What leads to burnout, and what can we do to help deal with it?

What leads to burnout, and what can we do to help deal with it?

What do we need to know about telederm?

What do we need to know about telederm?

What advice would you give a young dermatologist who wants to get involved in leadership in our specialty?

What advice would you give a young dermatologist who wants to get involved in leadership in our specialty?

In your opinion, what is the most worrisome trend in Healthcare?

In your opinion, what is the most worrisome trend in Healthcare?

What is Camp Discovery, and how can I get involved?

What is Camp Discovery, and how can I get involved?

What are the advocacy priorities of the AAD?

What are the advocacy priorities of the AAD?

How are PBMs and Health insurance companies related to one another?

How are PBMs and Health insurance companies related to one another?

What is Sequestration, when can we expect it to end?

What is Sequestration, when can we expect it to end?

What is Budget neutrality, and how does it affect our reimbursement?

What is Budget neutrality, and how does it affect our reimbursement?

How do I get involved with the AAD?

How do I get involved with the AAD?

What is the role of diet and environment in the pathogenesis of AD?

What is the role of diet and environment in the pathogenesis of AD?

Do you recommend getting a CBC before using topical ruxolitinib in patients with a history of thrombocytopenia, anemia or neutropenia?

Do you recommend getting a CBC before using topical ruxolitinib in patients with a history of thrombocytopenia, anemia or neutropenia?

Are there any complementary and alternative therapies which have data showing efficacy in the treatment of AD?

Are there any complementary and alternative therapies which have data showing efficacy in the treatment of AD?

Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Does tralokinumab have a higher rate of conjunctivitis versus dupilumab?

Does tralokinumab have a higher rate of conjunctivitis versus dupilumab?

Does topical ruxolitinib work for pruritus or pruritic disorders?

Does topical ruxolitinib work for pruritus or pruritic disorders?

Is topical ruxolitinib safe for use on the face, armpit or groin?

Is topical ruxolitinib safe for use on the face, armpit or groin?

Is topical ruxolitinib still effective if only used once a day for atopic dermatitis?

Is topical ruxolitinib still effective if only used once a day for atopic dermatitis?

Should you perform total body skin exams on patients to screen for skin cancer in patients using topical ruxolitinib?

Should you perform total body skin exams on patients to screen for skin cancer in patients using topical ruxolitinib?

Are there differences in the genetic risk factors for atopic dermatitis in Skin of Color patients?

Are there differences in the genetic risk factors for atopic dermatitis in Skin of Color patients?

Are there differences in the burden of atopic dermatitis by race?

Are there differences in the burden of atopic dermatitis by race?

Are there any head-to-head studies that look at the efficacy of topical ruxolitinib cream compared to a topical steroid?

Are there any head-to-head studies that look at the efficacy of topical ruxolitinib cream compared to a topical steroid?

Are there differences in atopic dermatitis molecular and cellular markers in Skin of Color patients?

Are there differences in atopic dermatitis molecular and cellular markers in Skin of Color patients?

How does topical ruxolitinib address pruritus so quickly?

How does topical ruxolitinib address pruritus so quickly?

Did the AD pivotal trials enroll adequate numbers of diverse patients?

Did the AD pivotal trials enroll adequate numbers of diverse patients?

How long before AD patients experience improvement in pruritus after beginning treatment with topical ruxolitinib cream?

How long before AD patients experience improvement in pruritus after beginning treatment with topical ruxolitinib cream?

What should l tell patients concerned about systemic absorption of topical medications?

What should l tell patients concerned about systemic absorption of topical medications?

Are there any natural options to treat atopic dermatitis?

Are there any natural options to treat atopic dermatitis?

Can emollients be used in conjunction with topical ruxolitinib cream?

Can emollients be used in conjunction with topical ruxolitinib cream?

If a patient is on oral spironolactone and is trying to conceive, how long before that should they stop the spironolactone?

If a patient is on oral spironolactone and is trying to conceive, how long before that should they stop the spironolactone?

How do you stagger Poly-L-lactic acid treatments with hyaluronic acid and botox?

How do you stagger Poly-L-lactic acid treatments with hyaluronic acid and botox?

How do you counsel patients on their skincare regimen?

How do you counsel patients on their skincare regimen?

If you treat a rosacea patient with a laser do you stop other concomitant rosacea treatments?

If you treat a rosacea patient with a laser do you stop other concomitant rosacea treatments?

What are some common triggers for worsening of atopic dermatitis?

What are some common triggers for worsening of atopic dermatitis?

Do you patch test patients while on dupilumab?

Do you patch test patients while on dupilumab?

Do you see persistent facial dermatitis in AD patients who have responded to dupilumab?

Do you see persistent facial dermatitis in AD patients who have responded to dupilumab?

Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares?

Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares?

What do you do for patients on dupilumab who develop a psoriasis phenotype and biopsy indicative of psoriasis?

What do you do for patients on dupilumab who develop a psoriasis phenotype and biopsy indicative of psoriasis?

Have you combined dupilumab with any other systemic anti-inflammatories for partial responders to dupilumab?

Have you combined dupilumab with any other systemic anti-inflammatories for partial responders to dupilumab?

How do you combine thread lifts with hyaluronic acid fillers?

How do you combine thread lifts with hyaluronic acid fillers?

Do you recommend treating cheeks and tear trough with hyaluronic acid filler?

Do you recommend treating cheeks and tear trough with hyaluronic acid filler?

What are some clinical tips to help identify and/or uncover whether patients have intertriginous psoriasis so that these areas are not overlooked or avoided?

What are some clinical tips to help identify and/or uncover whether patients have intertriginous psoriasis so that these areas are not overlooked or avoided?

Is there any evidence that patients can build tolerance to topical roflumilast?

Is there any evidence that patients can build tolerance to topical roflumilast?

How can topical roflumilast impact quality of life in patients with psoriasis?

How can topical roflumilast impact quality of life in patients with psoriasis?

What advantages does topical roflumilast have over other topical treatments for psoriasis?

What advantages does topical roflumilast have over other topical treatments for psoriasis?

Can topical roflumilast be used as a first-line agent? Are all disease severities appropriate for topical roflumilast?

Can topical roflumilast be used as a first-line agent? Are all disease severities appropriate for topical roflumilast?

Does topical roflumilast have data that shows reduction of itch?

Does topical roflumilast have data that shows reduction of itch?

Which psoriasis symptoms are most burdensome for patients?

Which psoriasis symptoms are most burdensome for patients?

How durable is the efficacy of topical roflumilast for the long-term?

How durable is the efficacy of topical roflumilast for the long-term?

How do you discuss any safety concerns or warnings with patients prescribed ruxolitinib cream?

How do you discuss any safety concerns or warnings with patients prescribed ruxolitinib cream?

Have you heard about reports of crystals in ruxolitinib cream?

Have you heard about reports of crystals in ruxolitinib cream?

Do you feel comfortable using topical ruxolitinib in combination with dupilumab?

Do you feel comfortable using topical ruxolitinib in combination with dupilumab?

Are there any body areas that you do not recommend ruxolitinib cream?

Are there any body areas that you do not recommend ruxolitinib cream?

Do you worry about systemic absorption with topical ruxolitinib?

Do you worry about systemic absorption with topical ruxolitinib?

How do you discuss potential stinging and burning with topical ruxolitinib use?

How do you discuss potential stinging and burning with topical ruxolitinib use?

Can topical ruxolitinib be used in pediatric patients?

Can topical ruxolitinib be used in pediatric patients?

What is the Aron Regimen?

What is the Aron Regimen?

What excites you most about the approval of topical roflumilast?

What excites you most about the approval of topical roflumilast?

Which patients may benefit the most from topical roflumilast?

Which patients may benefit the most from topical roflumilast?

How effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas?

How effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas?

What is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors?

What is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors?

Are there any natural options for AD that you recommend?

Are there any natural options for AD that you recommend?

What are the current recommendations for elimination diets for kids with AD?

What are the current recommendations for elimination diets for kids with AD?

Can topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem?

Can topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem?

What is the overall safety and tolerability profile for topical roflumilast?

Do you augment oral and/or biologic therapy with a topical?

Do you augment oral and/or biologic therapy with a topical?

How do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic?

How do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic?

Can topical roflumilast be used for younger patients?

Can topical roflumilast be used for younger patients?

Is topical roflumilast safe for long-term use?

Is topical roflumilast safe for long-term use?

How important is the delivery vehicle for topical treatment of psoriasis?

How important is the delivery vehicle for topical treatment of psoriasis?

Does topical roflumilast treat pruritus associated with psoriasis?

Does topical roflumilast treat pruritus associated with psoriasis?

Does topical roflumilast have data that supports its safety and efficacy for long-term use?

Does topical roflumilast have data that supports its safety and efficacy for long-term use?

There has been increased emphasis placed on treatment of plaque psoriasis in intertriginous and/or genital areas. How do you approach management of disease in these areas?

There has been increased emphasis placed on treatment of plaque psoriasis in intertriginous and/or genital areas. How do you approach management of disease in these areas?

How is roflumilast different than other PDE4 inhibitors?

How is roflumilast different than other PDE4 inhibitors?

Topical roflumilast is indicated for patients 12 years and older. What is the significance of this as you think about topical treatment options for patients?

Topical roflumilast is indicated for patients 12 years and older. What is the significance of this as you think about topical treatment options for patients?

Are there any sensitizing ingredients or irritants in topical roflumilast and does it contain propylene glycol?

Are there any sensitizing ingredients or irritants in topical roflumilast and does it contain propylene glycol?

Did the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction?

Did the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction?

What are the advantages of topical roflumilast over traditional topical corticosteroids in the treatment of psoriasis?

What are the advantages of topical roflumilast over traditional topical corticosteroids in the treatment of psoriasis?

What is the incidence of metastatic SCC deaths compared to melanoma?

What is the incidence of metastatic SCC deaths compared to melanoma?

What’s your perception of the formulation/cream of topical roflumilast and why does this matter for patients?

What’s your perception of the formulation/cream of topical roflumilast and why does this matter for patients?

What is the long-term safety and efficacy data of topical roflumilast?

What is the long-term safety and efficacy data of topical roflumilast?

How quickly do patients see results with topical roflumilast?

How quickly do patients see results with topical roflumilast?

What is the overall tolerability of topical roflumilast and what are the most common side effects?

What is the overall tolerability of topical roflumilast and what are the most common side effects?

Which efficacy outcomes for topical roflumilast do you find most compelling and why?

Which efficacy outcomes for topical roflumilast do you find most compelling and why?

What is the I-IGA Success endpoint, and why is it important?

What is the I-IGA Success endpoint, and why is it important?

What were the efficacy outcomes for topical roflumilast in Phase 3 clinical trials?

What were the efficacy outcomes for topical roflumilast in Phase 3 clinical trials?

What are the advantages of a once-daily, steroid-free topical?

What are the advantages of a once-daily, steroid-free topical?

How does your approach to treatment with topical roflumilast differ from treatment with topical steroids?

How does your approach to treatment with topical roflumilast differ from treatment with topical steroids?

What is topical roflumilast?

What is topical roflumilast?

Who is topical roflumilast approved for?

Who is topical roflumilast approved for?

How long should you give any biologic before you decide to switch agents?

How long should you give any biologic before you decide to switch agents?

What are your options for treating scars in your practice?

What are your options for treating scars in your practice?

When do you refer adjuvant radiation for squamous cells and small caliber nerves?

When do you refer adjuvant radiation for squamous cells and small caliber nerves?

Have you ever used combination therapy for hard-to-treat atopic dermatitis patients?

Have you ever used combination therapy for hard-to-treat atopic dermatitis patients?

How long do you keep patients on topical ruxolitinib who suffer from atopic dermatitis?

How long do you keep patients on topical ruxolitinib who suffer from atopic dermatitis?

Do you do any lab monitoring in patients prescribed topical ruxolitinib?

Do you do any lab monitoring in patients prescribed topical ruxolitinib?

How do you treat patients who have not seen success with dupilumab?

How do you treat patients who have not seen success with dupilumab?

How effective is topical ruxolitinib with itch experienced by patients who suffer from atopic dermatitis?

How effective is topical ruxolitinib with itch experienced by patients who suffer from atopic dermatitis?

Do you use topical ruxolitinib as a first line therapy for sensitive body areas?

Do you use topical ruxolitinib as a first line therapy for sensitive body areas?

How do you treat patients with both psoriasis and eczema, or eczema and inflammatory arthritis?

How do you treat patients with both psoriasis and eczema, or eczema and inflammatory arthritis?

Is there a limitation regarding body surface area with topical ruxolitinib?

Is there a limitation regarding body surface area with topical ruxolitinib?

Do you ever combine topical ruxolitinib with other systemic therapies?

Do you ever combine topical ruxolitinib with other systemic therapies?

What conversation do you have with your patients with regard to the safety of topical ruxolitinib?

What conversation do you have with your patients with regard to the safety of topical ruxolitinib?

How do you personalize a patient's skincare routine?

How do you personalize a patient's skincare routine?

What can you do to prevent muscle cramps in patients on vismodegib?

What can you do to prevent muscle cramps in patients on vismodegib?

When changing from an IL-17 to an IL-23 or vice versa, how long do you typically wait before initiating a new drug?

When changing from an IL-17 to an IL-23 or vice versa, how long do you typically wait before initiating a new drug?

Do contact dermatitis and atopic dermatitis commonly co-exist?

Do contact dermatitis and atopic dermatitis commonly co-exist?

What are the pros and cons of the different topical azelaic acid formulations?

What are the pros and cons of the different topical azelaic acid formulations?

What is your therapeutic algorithm for treating patients with hair loss?

What is your therapeutic algorithm for treating patients with hair loss?

Do you suggest checking potassium on patients on drospirenone containing OCP with concurrent use of spironolactone on healthy patients?

Do you suggest checking potassium on patients on drospirenone containing OCP with concurrent use of spironolactone on healthy patients?

What is your preferred treatment for acute guttate psoriasis?

What is your preferred treatment for acute guttate psoriasis?

What is the role of nutrition in dermatology?

What is the role of nutrition in dermatology?

What dose of spironolactone do you typically use in your acne patients?

What dose of spironolactone do you typically use in your acne patients?

Can you use ruxolitinib cream with a biologic agent?

Can you use ruxolitinib cream with a biologic agent?

How do you counsel patients with hair loss on their results?

How do you counsel patients with hair loss on their results?

Can you integrate hormonal therapy with sarecycline?

Can you integrate hormonal therapy with sarecycline?

Do you ever need to perform a skin biopsy on patients with atopic dermatitis?

Do you ever need to perform a skin biopsy on patients with atopic dermatitis?

How clinically relevant are the boxed warnings that are in the package insert with topical ruxolitinib cream?

How clinically relevant are the boxed warnings that are in the package insert with topical ruxolitinib cream?

Considering all the options that are available, when do you consider using topical ruxolitinib cream for treatment of atopic dermatitis?

Considering all the options that are available, when do you consider using topical ruxolitinib cream for treatment of atopic dermatitis?

Atopic dermatitis and vitiligo are very different disease states clinically. How is it that topical ruxolitinib cream shows efficacy in both of them?

Atopic dermatitis and vitiligo are very different disease states clinically. How is it that topical ruxolitinib cream shows efficacy in both of them?

How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information?

How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information?

Is it necessary to routinely treat atopic dermatitis with antimicrobial or antibiotic therapy to get patients to improve?

Is it necessary to routinely treat atopic dermatitis with antimicrobial or antibiotic therapy to get patients to improve?

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

What other diagnoses can be confused with atopic dermatitis?

What other diagnoses can be confused with atopic dermatitis?

Is it difficult to get access to topical ruxolitinib cream for patients through their insurance plans?

Is it difficult to get access to topical ruxolitinib cream for patients through their insurance plans?

With how much NS do you reconstitute your Dysport?

With how much NS do you reconstitute your Dysport?

I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?

I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?

What differences do you see clinically between topical ruxolitinib cream and other non-steroidal topical therapies used to treat atopic dermatitis?

What differences do you see clinically between topical ruxolitinib cream and other non-steroidal topical therapies used to treat atopic dermatitis?

How does Taltz compare head to head with Humira for psoriatic arthritis?

How does Taltz compare head to head with Humira for psoriatic arthritis?

What would be a suitable treatment option for psoriasis patients on Medicare?

What would be a suitable treatment option for psoriasis patients on Medicare?

If a patient has a family history of MS, would you treat the patient with a TNF Blocker or switch to something else?

If a patient has a family history of MS, would you treat the patient with a TNF Blocker or switch to something else?

Is there data on using calcipotriene cream vs ointment in combination with 5-FU and does the order of application matter?

Is there data on using calcipotriene cream vs ointment in combination with 5-FU and does the order of application matter?

Can you elaborate on the use of itraconazole in vismodigib-resistant BCCs?

Can you elaborate on the use of itraconazole in vismodigib-resistant BCCs?

SRT vs electronic brachytherapy?

SRT vs electronic brachytherapy?

SRT vs electronic brachytherapy?

SRT vs electronic brachytherapy?

Would you ever pair Dupixent with Otezla for atopic dermatitis?

Would you ever pair Dupixent with Otezla for atopic dermatitis?

How much normal saline do you use to reconstitute Dysport?

How much normal saline do you use to reconstitute Dysport?

How do you dose IVIG for dermatomyositis with and without myopathy?

How do you dose IVIG for dermatomyositis with and without myopathy?

Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS?

Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS?

Any reservations about using tirbanibulin ointment for actinic cheilitis?

Any reservations about using tirbanibulin ointment for actinic cheilitis?

Which hypochlorous acid spray do you use?

Which hypochlorous acid spray do you use?

Can you combine tapinarof with topical steroids?

Can you combine tapinarof with topical steroids?

Do you anticipate that you will be able to combine tapinarof and biologics?

Do you anticipate that you will be able to combine tapinarof and biologics?

Do you foresee any lab monitoring with tapinarof?

Do you foresee any lab monitoring with tapinarof?

Do you have patients wait a specified period of time between injections when switching biologics?

Do you have patients wait a specified period of time between injections when switching biologics?

Does tapinarof work for vitiligo?

Does tapinarof work for vitiligo?

What do you see as the biggest challenge to topical therapy use in psoriasis?

What do you see as the biggest challenge to topical therapy use in psoriasis?

Will tapinarof work for atopic dermatitis?

Will tapinarof work for atopic dermatitis?

Can you combine tapinarof and calcineurin inhibitors?

Can you combine tapinarof and calcineurin inhibitors?

How do you treat the folliculitis reported with tapinarof?

How do you treat the folliculitis reported with tapinarof?

Do you tell your patients to stop their biologic if they test positive for COVID?

Do you tell your patients to stop their biologic if they test positive for COVID?

Do you check bloodwork in patients on topical ruxolitinib?

Do you check bloodwork in patients on topical ruxolitinib?

How does ruxolitinib compare with topical calcineurin inhibitors and topical steroids?

How does ruxolitinib compare with topical calcineurin inhibitors and topical steroids?

Does ruxolitinib cream work for psoriasis?

Does ruxolitinib cream work for psoriasis?

Can you combine topical ruxolitinib with topical calcineurin inhibitors?

Can you combine topical ruxolitinib with topical calcineurin inhibitors?

Can you combine topical ruxolitinib with topical corticosteroids?

Can you combine topical ruxolitinib with topical corticosteroids?

Does ruxolitinib work for alopecia areata?

Does ruxolitinib work for alopecia areata?

Does ruxolitinib work for other granulomatous diseases like granuloma annulare or cutaneous sarcoid?

Does ruxolitinib work for other granulomatous diseases like granuloma annulare or cutaneous sarcoid?

Does ruxolitinib work for perioral dermatitis?

Does ruxolitinib work for perioral dermatitis?

Does ruxolitinib work for uremic pruritus?

Does ruxolitinib work for uremic pruritus?

Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Does ruxolitinib work for cutaneous lupus?

Does ruxolitinib work for cutaneous lupus?

What effect does COVID-19 have on rosacea?

What effect does COVID-19 have on rosacea?

How common is atopic dermatitis compared to psoriasis?

How common is atopic dermatitis compared to psoriasis?

For patients with extensive skin disease from dermatomyositis, are you still trying traditional immunosuppressants prior to moving to IVIG?

For patients with extensive skin disease from dermatomyositis, are you still trying traditional immunosuppressants prior to moving to IVIG?

Are there any recommendations on pulse dosing or giving vacations for hedgehog inhibitors to improve compliance and tolerability?

Are there any recommendations on pulse dosing or giving vacations for hedgehog inhibitors to improve compliance and tolerability?

What is the difference between Wynzora and Enstilar?

What is the difference between Wynzora and Enstilar?

If a patient develops a COVID-19 infection, should I stop my biologic?

If a patient develops a COVID-19 infection, should I stop my biologic?

What biologic medication (other than Humira) has worked best in your experience for your moderate to severe HS?

What biologic medication (other than Humira) has worked best in your experience for your moderate to severe HS?

Are there safety concerns with using biologics in patients with a history of melanoma?

Are there safety concerns with using biologics in patients with a history of melanoma?

How do you apply Duobrii lotion in order to avoid irritation?

How do you apply Duobrii lotion in order to avoid irritation?

Do you often add Enstilar or Duobrii to localized persistent areas while on biologics?

Do you often add Enstilar or Duobrii to localized persistent areas while on biologics?

Can you use roflumilast cream with topical steroids?

Can you use roflumilast cream with topical steroids?

Do you see tapinarof cream rivaling topical steroids for topical monotherapy in psoriasis and/or atopic dermatitis?

Do you see tapinarof cream rivaling topical steroids for topical monotherapy in psoriasis and/or atopic dermatitis?

Was the folliculitis reported in the tapinarof trials problematic?

Was the folliculitis reported in the tapinarof trials problematic?

Is the MOA of tapinarof better suited for psoriasis or atopic dermatitis?

Is the MOA of tapinarof better suited for psoriasis or atopic dermatitis?

When do you see patients back from lab work?

When do you see patients back from lab work?

Was the tolerability of tapinarof cream better for the trials?

Was the tolerability of tapinarof cream better for the trials?

Do you see tapinarof cream functioning more as a steroid-sparing topical the way tacrolimus, pimecrolimus and crisaborole do?

Do you see tapinarof cream functioning more as a steroid-sparing topical the way tacrolimus, pimecrolimus and crisaborole do?

I understand the suicides reported with psoriasis treatments were likely unrelated, but I am concerned about liability using it?

I understand the suicides reported with psoriasis treatments were likely unrelated, but I am concerned about liability using it?

Is there an ideal time to apply emollients?

Is there an ideal time to apply emollients?

What are the age indications for upcoming JAKs?

What are the age indications for upcoming JAKs?

Which areas of the body can you and can’t you apply ruxolitinib cream to?

Which areas of the body can you and can’t you apply ruxolitinib cream to?

Can you explain the different types of moisturizers for atopic dermatitis?

Can you explain the different types of moisturizers for atopic dermatitis?

Can you prescribe dupilumab to patients with a history of malignancy?

Can you prescribe dupilumab to patients with a history of malignancy?

In which patient populations should we be careful in prescribing ruxolitinib cream?

In which patient populations should we be careful in prescribing ruxolitinib cream?

How do you discuss ruxolitinib cream safety concerns with your patients?

How do you discuss ruxolitinib cream safety concerns with your patients?

What are the contraindications to ruxolitinib cream?

What are the contraindications to ruxolitinib cream?

How does ruxolitinib cream fit in your treatment algorithm for your atopic dermatitis patients?

How does ruxolitinib cream fit in your treatment algorithm for your atopic dermatitis patients?

What dermatoses are topical JAK inhibitors being investigated for?

What dermatoses are topical JAK inhibitors being investigated for?

How are noncompete agreements handled in dermatology practices?

How are noncompete agreements handled in dermatology practices?

How do you manage the diarrhea associated with apremilast?

How do you manage the diarrhea associated with apremilast?

Can you discuss your thoughts on the NEJM article on melanoma overdiagnosis and how GEP may fit into this?

Can you discuss your thoughts on the NEJM article on melanoma overdiagnosis and how GEP may fit into this?

Is there any basis to the concern about delayed nodules with the Voluma group of products?

Is there any basis to the concern about delayed nodules with the Voluma group of products?

What other topical medications with novel mechanisms of action are in the pipeline for atopic dermatitis?

What other topical medications with novel mechanisms of action are in the pipeline for atopic dermatitis?

What are the advantages of JAK therapy vs. monoclonal antibody therapy for atopic dermatitis?

What are the advantages of JAK therapy vs. monoclonal antibody therapy for atopic dermatitis?

Is there any data on contact dermatitis with use of topical JAK inhibitors for atopic dermatitis?

Is there any data on contact dermatitis with use of topical JAK inhibitors for atopic dermatitis?

Can pregnant patients use ruxolitinib cream?

Can pregnant patients use ruxolitinib cream?

How concerned are you about the risk of thrombosis mentioned in the boxed warning for ruxolitinib cream?

How concerned are you about the risk of thrombosis mentioned in the boxed warning for ruxolitinib cream?

Does atopic dermatitis always involve the flexural areas?

Does atopic dermatitis always involve the flexural areas?

Do people with atopic dermatitis always have atopic co-morbidities?

Do people with atopic dermatitis always have atopic co-morbidities?

Does atopic dermatitis always start in childhood?

Does atopic dermatitis always start in childhood?

How concerned are you about the risk of death mentioned in the boxed warning for ruxolitinib cream?

How concerned are you about the risk of death mentioned in the boxed warning for ruxolitinib cream?

Are stronger retinoids more effective for Post-Inflammatory Hyperpigmentation compared to weaker retinoids?

Are stronger retinoids more effective for Post-Inflammatory Hyperpigmentation compared to weaker retinoids?

Can you make a comment on rate of blindness in fat injections?

Can you make a comment on rate of blindness in fat injections?

Can you comment on the impact of biologics on COVID vaccine efficacy?

Can you comment on the impact of biologics on COVID vaccine efficacy?

Can you explain how the new 31 GEP reporting has changed and what it means?

Can you explain how the new 31 GEP reporting has changed and what it means?

Do you compound any currently available JAK inhibitors into creams for topical use by your patients?

Do you compound any currently available JAK inhibitors into creams for topical use by your patients?

Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?

Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?

Gwyneth Paltrow is promoting Xeomin as a 'natural' Botox. In my 13 years, we mostly use Xeomin for people that are resistant to Botox or Dysport. Thoughts?

Gwyneth Paltrow is promoting Xeomin as a 'natural' Botox. In my 13 years, we mostly use Xeomin for people that are resistant to Botox or Dysport. Thoughts?

Does a patient with latent TB need treatment before using ruxolitinib cream?

Does a patient with latent TB need treatment before using ruxolitinib cream?

Are topical JAK inhibitors, on the whole, more efficacious than superpotent topical steroids for atopic dermatitis?

Are topical JAK inhibitors, on the whole, more efficacious than superpotent topical steroids for atopic dermatitis?

How long after bathing do you recommend applying moisturizer?

How long after bathing do you recommend applying moisturizer?

What are the most common side effects of ruxolitinib cream?

What are the most common side effects of ruxolitinib cream?

Is topical ruxolitinib cream useful for patients with moderate disease?

Is topical ruxolitinib cream useful for patients with moderate disease?

How much does atopic dermatitis affect a patient’s quality of life?

How much does atopic dermatitis affect a patient’s quality of life?

Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Any tips for when patients won’t use their topicals due to burning with application?

Any tips for when patients won’t use their topicals due to burning with application?

Is ruxolitinib cream effective in treating itch associated with atopic dermatitis?

Is ruxolitinib cream effective in treating itch associated with atopic dermatitis?

How does treating atopic dermatitis in elderly patients differ from younger patient populations?

How does treating atopic dermatitis in elderly patients differ from younger patient populations?

What is the data on PLA positivity for dysplastic nevi?

What is the data on PLA positivity for dysplastic nevi?

Is hair recoverable in pattern hair loss?

Is hair recoverable in pattern hair loss?

How would you compare and contrast the utility of the information from 31-GEP vs. SLNB?

How would you compare and contrast the utility of the information from 31-GEP vs. SLNB?

How far laterally will you inject the frontalis?

How far laterally will you inject the frontalis?

How do you compound your topical JAK inhibitors like tofacitinib or ruxolitinib?

How do you compound your topical JAK inhibitors like tofacitinib or ruxolitinib?

How often do you recommend shampooing with seborrheic dermatitis?

How often do you recommend shampooing with seborrheic dermatitis?

Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what does that mean for my patients?

Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what does that mean for my patients?

How do you decide whether to use a JAK first line vs monoclonal antibody?

How do you decide whether to use a JAK first line vs monoclonal antibody?

What are the recommendations on how to monitor patients on oral JAK inhibitors?

What are the recommendations on how to monitor patients on oral JAK inhibitors?

Do you prescribe oral JAK inhibitors for your pediatric patients with vitiligo or alopecia areata?

Do you prescribe oral JAK inhibitors for your pediatric patients with vitiligo or alopecia areata?

What are the advantages of the Sensus device over older radiation therapy devices?

What are the advantages of the Sensus device over older radiation therapy devices?

What level of impact is teledermatology having on dermatology and will it persist?

What level of impact is teledermatology having on dermatology and will it persist?

Can hypochlorous acid products be useful for staphylococcus aureus decolonization and can they be sprayed on the scalp?

Can hypochlorous acid products be useful for staphylococcus aureus decolonization and can they be sprayed on the scalp?

How frequently do you recommend bathing children with atopic dermatitis?

How frequently do you recommend bathing children with atopic dermatitis?

How do you discuss PRP for hair loss with your patients?

How do you discuss PRP for hair loss with your patients?

Do you need to monitor any laboratory testing with topical JAK inhibitors?

Do you need to monitor any laboratory testing with topical JAK inhibitors?

Is there any evidence for the use of oral or systemic glutathione?

Is there any evidence for the use of oral or systemic glutathione?

How would you address live vaccines in pediatric patients on Ixekizumab?

How would you address live vaccines in pediatric patients on Ixekizumab?

Why does clascoterone work for acne and not minoxidil since they are both anti-androgens?

Why does clascoterone work for acne and not minoxidil since they are both anti-androgens?

Which cosmeceuticals do you recommend for lightening?

Which cosmeceuticals do you recommend for lightening?

How long do you allow patients to use hydroquinone 4% since melasma is a chronic disease that can last for years? Do you use "drug holidays"?

How long do you allow patients to use hydroquinone 4% since melasma is a chronic disease that can last for years? Do you use "drug holidays"?

What is your favorite biologic in those with treated latent TB?

What is your favorite biologic in those with treated latent TB?

Can dupilumab cause cutaneous T-cell lymphoma (CTCL)?

Can dupilumab cause cutaneous T-cell lymphoma (CTCL)?

How do you get oral JAKs covered by insurance for alopecia areata?

How do you get oral JAKs covered by insurance for alopecia areata?

What is your favorite biologic in geriatric patients?

What is your favorite biologic in geriatric patients?

How do I transition from cyclosporine to dupilumab for patients with atopic dermatitis?

How do I transition from cyclosporine to dupilumab for patients with atopic dermatitis?

What are your thoughts and dosage of finasteride for androgenetic alopecia in post-menopausal women?

What are your thoughts and dosage of finasteride for androgenetic alopecia in post-menopausal women?

Do you support dupilumab for all of the AD spectrum conditions if moderate-to-severe and failing?

Do you support dupilumab for all of the AD spectrum conditions if moderate-to-severe and failing?

How do you have your patients take oral tranexamic acid? Is there any benefit to splitting the 650 mg tablet?

How do you have your patients take oral tranexamic acid? Is there any benefit to splitting the 650 mg tablet?

Should we consider the JAK inhibitors more broadly immunosuppressive than the biologics?

Should we consider the JAK inhibitors more broadly immunosuppressive than the biologics?

Do patients need to be maintained on PRP therapy? If so, how often?

Do patients need to be maintained on PRP therapy? If so, how often?

Are there any differences in the side effect profiles between ABSORICA LD and traditional isotretinoin?

Are there any differences in the side effect profiles between ABSORICA LD and traditional isotretinoin?

Any tips on how to reduce the risk of ring warts?

Any tips on how to reduce the risk of ring warts?

Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients?

Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients?

How do you transition a psoriasis patient from methotrexate to a biologic? Can you use them concurrently?

How do you transition a psoriasis patient from methotrexate to a biologic? Can you use them concurrently?

Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients?

Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients?

Are you excited about delgocitinib?

Are you excited about delgocitinib?

Can you comment on hot topic of J Lo and her olive oil and non use of BOTOX?

Can you comment on hot topic of J Lo and her olive oil and non use of BOTOX?

How do you manage patients on biologics when they undergo orthopedic surgery? Do we need to hold the biologic?

How do you manage patients on biologics when they undergo orthopedic surgery? Do we need to hold the biologic?

Do you see WINLEVI replacing ACZONE?

Do you see WINLEVI replacing ACZONE?

Do you ever use triple therapy cream for Post-Inflammatory Hyperpigmentation?

Do you ever use triple therapy cream for Post-Inflammatory Hyperpigmentation?

Can you address potential long term side effects from finasteride after discontinuation?

Can you address potential long term side effects from finasteride after discontinuation?

How long should you hold dupilumab prior to live vaccine injection?

How long should you hold dupilumab prior to live vaccine injection?

Can AMZEEQ be combined with benzoyl peroxide?

Can AMZEEQ be combined with benzoyl peroxide?

How effective are home phototherapy/UV units for Vitiligo?

How effective are home phototherapy/UV units for Vitiligo?

Which toxin is best?

Which toxin is best?

How do you give folic acid with methotrexate?

How do you give folic acid with methotrexate?

What resources exist for those new to cosmetic procedures?

What resources exist for those new to cosmetic procedures?

How do you manage patients who develop candidiasis while on IL-17 inhibitors?

How do you manage patients who develop candidiasis while on IL-17 inhibitors?

How do you manage conjunctivitis that occurs while on dupilumab?

How do you manage conjunctivitis that occurs while on dupilumab?

Are JAK inhibitors (specifically tofacitinib or ruxolitinib) an effective treatment option for alopecia areata?

Are JAK inhibitors (specifically tofacitinib or ruxolitinib) an effective treatment option for alopecia areata?

When do you restart retinoids and azelaic acid after a chemical peel?

When do you restart retinoids and azelaic acid after a chemical peel?

CME & Education About Us

Loading profile...

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
CME Activities
Educational Resources
Community Resources
Our Expert Network

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved